Clinical	O
implications	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
human	O
leukemia	O
.	O

Glucorticoid	B-protein
receptors	I-protein
were	O
studied	O
in	O
various	O
populations	O
of	O
normal	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
and	O
leukemic	B-cell_type
lymphoblasts	I-cell_type
.	O

Normal	B-cell_type
lymphocytes	I-cell_type
contain	O
low	O
levels	O
of	O
glucocorticoid	B-protein
receptor	I-protein
(	O
approximately	O
2	O
,	O
500	O
sites/cell	O
)	O
which	O
are	O
identical	O
in	O
T-	O
and	O
non-T-fractions	O
.	O

Phytohemagglutinin	B-protein
treatment	O
increases	O
levels	O
about	O
3-fold	O
.	O

Leukemic	B-cell_type
lymphoblasts	I-cell_type
contain	O
larger	O
numbers	O
of	O
receptor	O
sites	O
.	O

Presence	O
of	O
receptor	O
is	O
correlated	O
with	O
in	O
vitro	O
sensitivitiy	O
to	O
glucocorticoids	O
and	O
in	O
vivo	O
response	O
to	O
therapy	O
.	O

Quantity	O
of	O
receptor	O
is	O
also	O
correlated	O
with	O
complete	O
remission	O
duration	O
independently	O
of	O
leukemic	B-cell_type
cell	I-cell_type
type	I-cell_type
(	O
T	O
or	O
null	O
)	O
,	O
initial	O
WBC	B-cell_type
,	O
or	O
age	O
of	O
patient	O
.	O

Quantitative	O
determination	O
of	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
in	O
acute	O
lymphoblastic	O
leukemia	O
may	O
be	O
of	O
value	O
both	O
as	O
an	O
independent	O
prognostic	O
variable	O
and	O
in	O
suggesting	O
which	O
patients	O
should	O
receive	O
glucocorticoid	O
therapy	O
.	O

[	NULL
CANCER	NULL
RESEARCH	NULL
38	NULL
,	NULL
4251-4256	NULL
,	NULL
November	NULL
1978	NULL
]	NULL
Clinical	NULL
Implications	NULL
of	NULL
Glucocorticoid	NULL
Receptors	NULL
in	NULL
Human	NULL
Leukemia	NULL
'	NULL
Marc	NULL
E.	NULL
Lippman	NULL
,	NULL
'	NULL
``	NULL
Geraldine	NULL
Konior	NULL
Yarbro	NULL
,	NULL
â€˜	NULL
a	NULL
and	NULL
Brigid	NULL
G.	NULL
Leventhal	NULL
Medicine	NULL
Branch	NULL
,	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
Bethesda	NULL
,	NULL
Maryland	NULL
20014	NULL
,	NULL
and	NULL
[	NULL
M.	NULL
E.	NULL
L.	NULL
]	NULL
,	NULL
Pediatric	NULL
Oncology	NULL
Division	NULL
,	NULL
Johns	NULL
Hopkins	NULL
Hospital	NULL
,	NULL
Baltimore	NULL
,	NULL
Maryland	NULL
21202	NULL
[	NULL
G.	NULL
K.	NULL
Y.	NULL
,	NULL
B.	NULL
G.	NULL
L.	NULL
]	NULL
Abstract	NULL
Glucocorticoid	NULL
receptors	NULL
were	NULL
studied	NULL
in	NULL
various	NULL
populations	NULL
of	NULL
normal	NULL
human	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
and	NULL
leukemic	NULL
lymphoblasts	NULL
.	NULL

Normal	NULL
lymphocytes	NULL
contain	NULL
low	NULL
levels	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
(	NULL
~2,500	NULL
sites/cell	NULL
)	NULL
which	NULL
are	NULL
identical	NULL
in	NULL
T-	NULL
and	NULL
non-T-fractions	NULL
.	NULL

Phytohemagglutinin	NULL
treatment	NULL
increases	NULL
levels	NULL
about	NULL
3-fold	NULL
.	NULL

Leukemic	NULL
lymphoblasts	NULL
contain	NULL
larger	NULL
numbers	NULL
of	NULL
receptor	NULL
sites	NULL
.	NULL

Presence	NULL
of	NULL
receptor	NULL
is	NULL
correlated	NULL
with	NULL
in	NULL
vitro	NULL
sensitivity	NULL
to	NULL
glucocorticoids	NULL
and	NULL
in	NULL
vivo	NULL
response	NULL
to	NULL
therapy	NULL
.	NULL

Quantity	NULL
of	NULL
receptor	NULL
is	NULL
also	NULL
correlated	NULL
with	NULL
complete	NULL
remission	NULL
duration	NULL
independently	NULL
of	NULL
leukemic	NULL
cell	NULL
type	NULL
(	NULL
T	NULL
or	NULL
null	NULL
)	NULL
,	NULL
initial	NULL
WBC	NULL
,	NULL
or	NULL
age	NULL
of	NULL
patient	NULL
.	NULL

Quantitative	NULL
determination	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
levels	NULL
in	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
may	NULL
be	NULL
of	NULL
value	NULL
both	NULL
as	NULL
an	NULL
independent	NULL
prognostic	NULL
variable	NULL
and	NULL
in	NULL
suggesting	NULL
which	NULL
patients	NULL
should	NULL
receive	NULL
glucocorticoid	NULL
therapy	NULL
.	NULL

Introduction	NULL
The	NULL
inhibitory	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
on	NULL
lymphoid	NULL
tissues	NULL
have	NULL
been	NULL
long	NULL
appreciated	NULL
(	NULL
25	NULL
,	NULL
29	NULL
)	NULL
.	NULL

Naturally	NULL
,	NULL
therefore	NULL
,	NULL
these	NULL
steroids	NULL
were	NULL
widely	NULL
used	NULL
in	NULL
the	NULL
management	NULL
of	NULL
acute	NULL
leukemia	NULL
when	NULL
it	NULL
became	NULL
apparent	NULL
that	NULL
they	NULL
could	NULL
also	NULL
kill	NULL
leukemic	NULL
lymphoblasts	NULL
(	NULL
6	NULL
,	NULL
10	NULL
)	NULL
.	NULL

Despite	NULL
this	NULL
useful	NULL
observation	NULL
there	NULL
are	NULL
certain	NULL
difficulties	NULL
in	NULL
their	NULL
effective	NULL
use	NULL
.	NULL

First	NULL
,	NULL
variable	NULL
response	NULL
rates	NULL
are	NULL
observed	NULL
in	NULL
patients	NULL
with	NULL
differing	NULL
histological	NULL
diagnoses	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Secondly	NULL
,	NULL
many	NULL
patients	NULL
whose	NULL
disease	NULL
is	NULL
initially	NULL
responsive	NULL
to	NULL
glucocorticoids	NULL
eventually	NULL
relapse	NULL
at	NULL
a	NULL
later	NULL
point	NULL
in	NULL
their	NULL
clinical	NULL
course	NULL
with	NULL
steroid-resistant	NULL
celts	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
while	NULL
initial	NULL
response	NULL
rates	NULL
in	NULL
ALL*	NULL
range	NULL
between	NULL
45	NULL
and	NULL
65	NULL
%	NULL
,	NULL
after	NULL
relapse	NULL
the	NULL
rate	NULL
of	NULL
remission	NULL
induction	NULL
with	NULL
glucocorticoids	NULL
alone	NULL
falis	NULL
to	NULL
25	NULL
%	NULL
.	NULL

Furthermore	NULL
,	NULL
steroid	NULL
administration	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
host	NULL
of	NULL
iatrogenic	NULL
complications	NULL
,	NULL
including	NULL
immunosuppression	NULL
with	NULL
concomitant	NULL
nosocom-ial	NULL
infections	NULL
,	NULL
Cushing	NULL
's	NULL
syndrome	NULL
,	NULL
diabetes	NULL
mellitus	NULL
,	NULL
poor	NULL
wound	NULL
healing	NULL
,	NULL
peptic	NULL
ulcer	NULL
disease	NULL
,	NULL
psychosis	NULL
,	NULL
and	NULL
other	NULL
problems	NULL
(	NULL
1	NULL
,	NULL
13	NULL
)	NULL
.	NULL

These	NULL
untoward	NULL
reactions	NULL
become	NULL
particularly	NULL
vexatious	NULL
when	NULL
it	NULL
is	NULL
recalled	NULL
that	NULL
most	NULL
leukemic	NULL
and	NULL
related	NULL
disorders	NULL
are	NULL
managed	NULL
by	NULL
combinations	NULL
of	NULL
cytotoxic	NULL
therapy	NULL
which	NULL
include	NULL
glucocorticoids	NULL
along	NULL
with	NULL
several	NULL
other	NULL
agents	NULL
.	NULL

Thus	NULL
,	NULL
possibly	NULL
harmful	NULL
components	NULL
of	NULL
a	NULL
drug	NULL
combination	NULL
may	NULL
be	NULL
continued	NULL
long	NULL
after	NULL
they	NULL
have	NULL
ceased	NULL
to	NULL
be	NULL
useful	NULL
.	NULL

Quite	NULL
obviously	NULL
,	NULL
it	NULL
would	NULL
be	NULL
of	NULL
value	NULL
to	NULL
predict	NULL
'	NULL
Presented	NULL
at	NULL
the	NULL
John	NULL
E.	NULL
Fogarty	NULL
International	NULL
Center	NULL
Conference	NULL
on	NULL
Hormones	NULL
and	NULL
Cancer	NULL
,	NULL
March	NULL
29	NULL
to	NULL
31	NULL
,	NULL
1978	NULL
,	NULL
Bethesda	NULL
,	NULL
Md	NULL
.	NULL

*	NULL
To	NULL
whom	NULL
requests	NULL
for	NULL
reprints	NULL
should	NULL
be	NULL
addressed	NULL
,	NULL
at	NULL
Medical	NULL
Breast	NULL
Cancer	NULL
Section	NULL
,	NULL
Building	NULL
10	NULL
,	NULL
Room	NULL
6B02	NULL
,	NULL
NIH	NULL
,	NULL
Bethesda	NULL
,	NULL
Md	NULL
.	NULL

20014	NULL
.	NULL

*	NULL
Deceased	NULL
.	NULL

*	NULL
The	NULL
abbreviation	NULL
used	NULL
is	NULL
:	NULL
ALL	NULL
,	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
.	NULL

NOVEMBER	NULL
1978	NULL
in	NULL
advance	NULL
which	NULL
leukemic	NULL
cells	NULL
might	NULL
be	NULL
inhibited	NULL
by	NULL
glucocorticoids	NULL
and	NULL
thus	NULL
restrict	NULL
their	NULL
use	NULL
to	NULL
beneficial	NULL
situations	NULL
.	NULL

Clearly	NULL
,	NULL
an	NULL
in	NULL
vitro	NULL
test	NULL
of	NULL
glucocorticoid	NULL
leukemic	NULL
cell	NULL
cytotoxicity	NULL
would	NULL
seem	NULL
worthwhile	NULL
,	NULL
but	NULL
thus	NULL
far	NULL
such	NULL
methods	NULL
have	NULL
not	NULL
been	NULL
widely	NULL
adopted	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
.	NULL

It	NULL
is	NULL
difficult	NULL
to	NULL
reliably	NULL
culture	NULL
leukemic	NULL
cell	NULL
populations	NULL
and	NULL
,	NULL
furthermore	NULL
,	NULL
in	NULL
vitro	NULL
effects	NULL
of	NULL
hormones	NULL
may	NULL
not	NULL
be	NULL
as	NULL
easily	NULL
demonstrated	NULL
as	NULL
in	NULL
vivo	NULL
responses	NULL
.	NULL

Studies	NULL
performed	NULL
in	NULL
breast	NULL
cancer	NULL
supported	NULL
the	NULL
notion	NULL
that	NULL
quantification	NULL
of	NULL
specific	NULL
steroid	NULL
receptors	NULL
for	NULL
estrogen	NULL
was	NULL
useful	NULL
in	NULL
predicting	NULL
response	NULL
to	NULL
endocrine	NULL
therapy	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Based	NULL
upon	NULL
this	NULL
fact	NULL
,	NULL
plus	NULL
a	NULL
clearer	NULL
understanding	NULL
of	NULL
the	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
glucocorticoids	NULL
(	NULL
26	NULL
,	NULL
35	NULL
)	NULL
,	NULL
it	NULL
appeared	NULL
worthwhile	NULL
to	NULL
examine	NULL
human	NULL
leukemic	NULL
cells	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
and	NULL
to	NULL
see	NULL
whether	NULL
their	NULL
presence	NULL
was	NULL
correlated	NULL
with	NULL
glucocorticoid	NULL
responsiveness	NULL
.	NULL

This	NULL
study	NULL
briefly	NULL
summarizes	NULL
our	NULL
prior	NULL
work	NULL
in	NULL
characterizing	NULL
the	NULL
glucocorticoid	NULL
receptors	NULL
of	NULL
human	NULL
leukemic	NULL
cells	NULL
and	NULL
outlines	NULL
some	NULL
of	NULL
our	NULL
more	NULL
recent	NULL
data	NULL
correlating	NULL
steroid	NULL
receptors	NULL
with	NULL
clinical	NULL
features	NULL
of	NULL
the	NULL
patients	NULL
'	NULL
illness	NULL
.	NULL

Much	NULL
of	NULL
our	NULL
eartier	NULL
work	NULL
has	NULL
recently	NULL
been	NULL
reviewed	NULL
(	NULL
16	NULL
)	NULL
,	NULL
and	NULL
for	NULL
this	NULL
reason	NULL
most	NULL
of	NULL
our	NULL
effort	NULL
will	NULL
be	NULL
aimed	NULL
at	NULL
presenting	NULL
more	NULL
recent	NULL
studies	NULL
.	NULL

Glucocorticoid	NULL
Receptors	NULL
in	NULL
ALL	NULL
Because	NULL
of	NULL
the	NULL
high	NULL
initial	NULL
response	NULL
rate	NULL
of	NULL
ALL	NULL
to	NULL
glucocorticoids	NULL
and	NULL
general	NULL
patient	NULL
availability	NULL
,	NULL
we	NULL
initially	NULL
chose	NULL
to	NULL
examine	NULL
cells	NULL
from	NULL
these	NULL
patients	NULL
for	NULL
glucocorticoid	NULL
receptors	NULL
(	NULL
19-21	NULL
)	NULL
.	NULL

With	NULL
the	NULL
use	NULL
of	NULL
a	NULL
competitive	NULL
protein	NULL
binding	NULL
assay	NULL
on	NULL
cytoplasmic	NULL
extracts	NULL
prepared	NULL
from	NULL
either	NULL
viably	NULL
frozen	NULL
or	NULL
fresh	NULL
lymphoblasts	NULL
,	NULL
it	NULL
was	NULL
possible	NULL
to	NULL
demonstrate	NULL
saturable	NULL
binding	NULL
of	NULL
radiolabeled	NULL
glucocorticoid	NULL
.	NULL

All	NULL
samples	NULL
from	NULL
patients	NULL
with	NULL
untreated	NULL
ALL	NULL
contained	NULL
saturable	NULL
receptor	NULL
sites	NULL
which	NULL
ranged	NULL
in	NULL
concentration	NULL
between	NULL
about	NULL
0.12	NULL
and	NULL
0.8	NULL
pmol	NULL
[	NULL
Â°H	NULL
]	NULL
dexamethasone	NULL
bound	NULL
per	NULL
mg	NULL
of	NULL
cytoplasmic	NULL
protein	NULL
.	NULL

We	NULL
estimated	NULL
about	NULL
1	NULL
x	NULL
10-Â®	NULL
mg	NULL
of	NULL
cytoplasmic	NULL
protein	NULL
per	NULL
cell	NULL
(	NULL
based	NULL
on	NULL
cell	NULL
count	NULL
and	NULL
Lowry	NULL
protein	NULL
determination	NULL
)	NULL
.	NULL

This	NULL
would	NULL
correspond	NULL
to	NULL
between	NULL
about	NULL
1,000	NULL
and	NULL
8,000	NULL
sites/cell	NULL
.	NULL

The	NULL
binding	NULL
data	NULL
obtained	NULL
,	NULL
when	NULL
plotted	NULL
with	NULL
the	NULL
use	NULL
of	NULL
the	NULL
Scatchard	NULL
tech-nique	NULL
,	NULL
were	NULL
best	NULL
fitted	NULL
by	NULL
a	NULL
straight	NULL
line	NULL
,	NULL
suggesting	NULL
that	NULL
binding	NULL
was	NULL
to	NULL
a	NULL
class	NULL
of	NULL
receptor	NULL
sites	NULL
of	NULL
uniform	NULL
affinity	NULL
.	NULL

The	NULL
equilibrium	NULL
dissociation	NULL
constant	NULL
(	NULL
K	NULL
,	NULL
,	NULL
)	NULL
of	NULL
this	NULL
receptor	NULL
ranged	NULL
between	NULL
2	NULL
and	NULL
8	NULL
nm	NULL
in	NULL
various	NULL
experiments	NULL
when	NULL
[	NULL
*HIdexamethasone	NULL
was	NULL
used	NULL
as	NULL
the	NULL
ligand	NULL
and	NULL
was	NULL
increased	NULL
about	NULL
10-fold	NULL
when	NULL
[	NULL
*HJcortisol	NULL
was	NULL
employed	NULL
.	NULL

An	NULL
equilibrium	NULL
dissociation	NULL
constant	NULL
not	NULL
significantly	NULL
different	NULL
from	NULL
those	NULL
values	NULL
was	NULL
obtained	NULL
from	NULL
the	NULL
quotient	NULL
of	NULL
the	NULL
measured	NULL
association	NULL
and	NULL
dissociation	NULL
rate	NULL
constants	NULL
(	NULL
19	NULL
)	NULL
.	NULL

This	NULL
suggested	NULL
that	NULL
true	NULL
equilibrium	NULL
conditions	NULL
were	NULL
met	NULL
with	NULL
the	NULL
use	NULL
of	NULL
our	NULL
assay	NULL
methodology	NULL
.	NULL

This	NULL
binding	NULL
component	NULL
was	NULL
sensitive	NULL
to	NULL
proteolytic	NULL
digestion	NULL
with	NULL
trypsin	NULL
,	NULL
4251	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1978	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

M.	NULL
E.	NULL
Lippman	NULL
et	NULL
al	NULL
.	NULL

chymotrypsin	NULL
,	NULL
or	NULL
papain	NULL
,	NULL
but	NULL
resistant	NULL
to	NULL
RNase	NULL
,	NULL
DNase	NULL
,	NULL
and	NULL
phospholipase	NULL
A	NULL
,	NULL
C	NULL
,	NULL
or	NULL
D	NULL
treatments	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
receptor	NULL
was	NULL
a	NULL
protein	NULL
.	NULL

Mercuric	NULL
chloride	NULL
preincubation	NULL
obliterated	NULL
specific	NULL
binding	NULL
while	NULL
sulfhydryl	NULL
reagents	NULL
and	NULL
glycerol	NULL
up	NULL
to	NULL
20	NULL
%	NULL
concentration	NULL
stabilized	NULL
binding	NULL
activity	NULL
.	NULL

While	NULL
high-affinity	NULL
binding	NULL
is	NULL
certainly	NULL
an	NULL
important	NULL
criterion	NULL
for	NULL
a	NULL
steroid	NULL
receptor	NULL
,	NULL
it	NULL
alone	NULL
is	NULL
insufficient	NULL
to	NULL
establish	NULL
with	NULL
certainty	NULL
that	NULL
the	NULL
binding	NULL
component	NULL
is	NULL
functioning	NULL
as	NULL
a	NULL
receptor	NULL
.	NULL

For	NULL
example	NULL
,	NULL
plasma	NULL
transport	NULL
proteins	NULL
such	NULL
as	NULL
transcortin	NULL
or	NULL
corticosteroid-binding	NULL
globulin	NULL
can	NULL
also	NULL
bind	NULL
natural	NULL
glucocorticoid	NULL
with	NULL
high	NULL
affinity	NULL
.	NULL

For	NULL
this	NULL
reason	NULL
the	NULL
specificity	NULL
of	NULL
binding	NULL
was	NULL
examined	NULL
in	NULL
detail	NULL
(	NULL
19	NULL
)	NULL
.	NULL

All	NULL
biologically	NULL
active	NULL
glucocorticoids	NULL
tested	NULL
competed	NULL
with	NULL
either	NULL
[	NULL
*H	NULL
]	NULL
cortisol	NULL
or	NULL
[	NULL
*H	NULL
)	NULL
}	NULL
dexamethasone	NULL
for	NULL
binding	NULL
.	NULL

Unlabeled	NULL
triamcinolone	NULL
and	NULL
dexamethasone	NULL
,	NULL
fluorinated	NULL
synthetic	NULL
glucocorticoids	NULL
with	NULL
very	NULL
low	NULL
affinity	NULL
for	NULL
corticosteroid-binding	NULL
globulin	NULL
,	NULL
showed	NULL
a	NULL
higher	NULL
apparent	NULL
affinity	NULL
for	NULL
the	NULL
receptor	NULL
than	NULL
did	NULL
cortisol	NULL
itself	NULL
.	NULL

This	NULL
parallels	NULL
their	NULL
known	NULL
increased	NULL
biological	NULL
potency	NULL
.	NULL

The	NULL
receptor	NULL
showed	NULL
little	NULL
apparent	NULL
affinity	NULL
for	NULL
compounds	NULL
without	NULL
glucocorticoid	NULL
activity	NULL
such	NULL
as	NULL
metabolites	NULL
(	NULL
tetrahydrocortisol	NULL
)	NULL
or	NULL
inactive	NULL
stereoisomers	NULL
(	NULL
11a-hydroxycortisol	NULL
)	NULL
.	NULL

Both	NULL
progesterone	NULL
and	NULL
cortexolone	NULL
,	NULL
which	NULL
are	NULL
inactive	NULL
as	NULL
glucocorticoids	NULL
but	NULL
act	NULL
as	NULL
antiinducers	NULL
in	NULL
rodent	NULL
lymphoid	NULL
cells	NULL
(	NULL
26	NULL
)	NULL
,	NULL
were	NULL
effective	NULL
competitors	NULL
for	NULL
binding	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
cytosolic	NULL
binding	NULL
component	NULL
readily	NULL
distinguished	NULL
between	NULL
cortisone	NULL
and	NULL
cortisol	NULL
or	NULL
prednisone	NULL
and	NULL
prednisolone	NULL
,	NULL
showing	NULL
that	NULL
reduction	NULL
of	NULL
the	NULL
11-keto	NULL
group	NULL
(	NULL
which	NULL
is	NULL
necessary	NULL
for	NULL
biological	NULL
activity	NULL
)	NULL
is	NULL
necessary	NULL
for	NULL
optimal	NULL
binding	NULL
.	NULL

Thus	NULL
,	NULL
there	NULL
are	NULL
close	NULL
correlations	NULL
between	NULL
extent	NULL
of	NULL
binding	NULL
and	NULL
biological	NULL
effect	NULL
.	NULL

Using	NULL
this	NULL
cytoplasmic	NULL
assay	NULL
we	NULL
examined	NULL
the	NULL
leukemic	NULL
blast	NULL
cells	NULL
of	NULL
22	NULL
patients	NULL
for	NULL
cytosolic	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

All	NULL
patients	NULL
had	NULL
some	NULL
detectable	NULL
receptor	NULL
(	NULL
minimum	NULL
0.12	NULL
pmol	NULL
[	NULL
Â°H	NULL
]	NULL
dexamethasone	NULL
bound	NULL
per	NULL
mg	NULL
of	NULL
cytoplasmic	NULL
protein	NULL
)	NULL
.	NULL

Average	NULL
binding	NULL
in	NULL
these	NULL
untreated	NULL
patients	NULL
was	NULL
0.31	NULL
+	NULL
0.1	NULL
(	NULL
S.D	NULL
.	NULL
)	NULL

pmol	NULL
per	NULL
mg	NULL
cytosol	NULL
protein	NULL
.	NULL

All	NULL
of	NULL
these	NULL
patients	NULL
subsequently	NULL
responded	NULL
to	NULL
an	NULL
initial	NULL
attempt	NULL
at	NULL
induction	NULL
chemotherapy	NULL
with	NULL
a	NULL
drug	NULL
combination	NULL
including	NULL
glucocorticoid	NULL
.	NULL

Six	NULL
other	NULL
patients	NULL
were	NULL
studied	NULL
at	NULL
the	NULL
time	NULL
of	NULL
leukemic	NULL
relapse	NULL
.	NULL

At	NULL
this	NULL
time	NULL
,	NULL
leukemic	NULL
cells	NULL
were	NULL
studied	NULL
prior	NULL
to	NULL
a	NULL
reinduction	NULL
attempt	NULL
with	NULL
a	NULL
drug	NULL
combination	NULL
including	NULL
a	NULL
glucocorticoid	NULL
.	NULL

These	NULL
6	NULL
patients	NULL
subsequently	NULL
achieved	NULL
a	NULL
complete	NULL
remission	NULL
on	NULL
this	NULL
therapy	NULL
.	NULL

Their	NULL
average	NULL
glucocorticoid	NULL
binding	NULL
activity	NULL
was	NULL
0.30	NULL
+	NULL
0.12	NULL
pmol	NULL
of	NULL
[	NULL
*H	NULL
]	NULL
dexamethasone	NULL
per	NULL
mg	NULL
of	NULL
cytoplasmic	NULL
protein	NULL
,	NULL
a	NULL
value	NULL
not	NULL
significantly	NULL
different	NULL
from	NULL
that	NULL
in	NULL
previously	NULL
untreated	NULL
patients	NULL
.	NULL

Six	NULL
additional	NULL
patients	NULL
were	NULL
studied	NULL
at	NULL
the	NULL
time	NULL
of	NULL
relapse	NULL
who	NULL
subsequently	NULL
failed	NULL
to	NULL
achieve	NULL
a	NULL
remission	NULL
on	NULL
an	NULL
identical	NULL
drug	NULL
combination	NULL
which	NULL
included	NULL
glucocorticoid	NULL
.	NULL

Glucocorticoid	NULL
binding	NULL
activity	NULL
in	NULL
these	NULL
patients	NULL
was	NULL
0.015	NULL
+	NULL
0.0095	NULL
pmol	NULL
[	NULL
Â°H	NULL
]	NULL
dexamethasone	NULL
bound	NULL
per	NULL
mg	NULL
of	NULL
cytoplasmic	NULL
protein	NULL
.	NULL

One	NULL
patient	NULL
was	NULL
studied	NULL
on	NULL
3	NULL
separate	NULL
occasions	NULL
(	NULL
his	NULL
initial	NULL
presentation	NULL
,	NULL
first	NULL
relapse	NULL
,	NULL
and	NULL
second	NULL
relapse	NULL
)	NULL
.	NULL

Induction	NULL
therapy	NULL
was	NULL
attempted	NULL
with	NULL
the	NULL
identical	NULL
drug	NULL
combination	NULL
,	NULL
including	NULL
prednisolone	NULL
in	NULL
each	NULL
case	NULL
.	NULL

At	NULL
presentation	NULL
,	NULL
binding	NULL
activity	NULL
was	NULL
0.32	NULL
,	NULL
at	NULL
first	NULL
relapse	NULL
0.40	NULL
,	NULL
and	NULL
at	NULL
second	NULL
relapse	NULL
0	NULL
pmol	NULL
[	NULL
Â°H	NULL
]	NULL
dexamethasone	NULL
bound	NULL
per	NULL
mg	NULL
of	NULL
cytoplasmic	NULL
protein	NULL
.	NULL

Induction	NULL
was	NULL
successful	NULL
initially	NULL
and	NULL
at	NULL
the	NULL
time	NULL
of	NULL
first	NULL
relapse	NULL
,	NULL
but	NULL
the	NULL
patient	NULL
showed	NULL
no	NULL
benefi-	NULL
4252	NULL
cial	NULL
response	NULL
to	NULL
therapy	NULL
on	NULL
the	NULL
second	NULL
attempt	NULL
at	NULL
reinduction	NULL
therapy	NULL
.	NULL

With	NULL
the	NULL
exception	NULL
of	NULL
this	NULL
particular	NULL
patient	NULL
,	NULL
one	NULL
can	NULL
not	NULL
conclude	NULL
that	NULL
the	NULL
intervening	NULL
therapy	NULL
had	NULL
selected	NULL
out	NULL
a	NULL
subpopulation	NULL
of	NULL
receptor	NULL
deficient	NULL
cells	NULL
.	NULL

As	NULL
will	NULL
be	NULL
shown	NULL
later	NULL
,	NULL
it	NULL
is	NULL
probable	NULL
that	NULL
in	NULL
some	NULL
cases	NULL
relapse	NULL
may	NULL
occur	NULL
in	NULL
association	NULL
with	NULL
preexistent	NULL
low	NULL
receptor	NULL
levels	NULL
.	NULL

Thus	NULL
,	NULL
there	NULL
appeared	NULL
to	NULL
be	NULL
a	NULL
good	NULL
correlation	NULL
between	NULL
response	NULL
to	NULL
therapy	NULL
and	NULL
the	NULL
presence	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

This	NULL
is	NULL
a	NULL
somewhat	NULL
surprising	NULL
result	NULL
given	NULL
the	NULL
fact	NULL
that	NULL
these	NULL
patients	NULL
were	NULL
not	NULL
managed	NULL
with	NULL
single	NULL
agent	NULL
therapy	NULL
,	NULL
but	NULL
received	NULL
drug	NULL
combinations	NULL
including	NULL
agents	NULL
which	NULL
have	NULL
no	NULL
apparent	NULL
biochemical	NULL
cross-resist-ance	NULL
with	NULL
glucocorticoids	NULL
(	NULL
vincristine	NULL
,	NULL
methotrexate	NULL
,	NULL
and	NULL
6-mercaptopurine	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
resistance	NULL
to	NULL
glucocorticoids	NULL
would	NULL
not	NULL
necessarily	NULL
be	NULL
correlated	NULL
with	NULL
either	NULL
resistance	NULL
to	NULL
other	NULL
components	NULL
of	NULL
the	NULL
drug	NULL
combination	NULL
employed	NULL
or	NULL
failure	NULL
to	NULL
observe	NULL
a	NULL
clinical	NULL
response	NULL
.	NULL

In	NULL
order	NULL
to	NULL
learn	NULL
the	NULL
biological	NULL
significance	NULL
of	NULL
these	NULL
receptor	NULL
levels	NULL
we	NULL
sought	NULL
to	NULL
quantitate	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
on	NULL
human	NULL
leukemic	NULL
blast	NULL
cells	NULL
with	NULL
the	NULL
use	NULL
of	NULL
a	NULL
direct	NULL
in	NULL
vitro	NULL
assay	NULL
.	NULL

Since	NULL
inhibition	NULL
of	NULL
nucleoside	NULL
incorporation	NULL
had	NULL
been	NULL
shown	NULL
by	NULL
other	NULL
investigators	NULL
to	NULL
be	NULL
an	NULL
early	NULL
effect	NULL
of	NULL
glucocorticoids	NULL
on	NULL
responsive	NULL
lymphoid	NULL
cells	NULL
(	NULL
28	NULL
,	NULL
34	NULL
)	NULL
,	NULL
we	NULL
measured	NULL
[	NULL
Â°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
in	NULL
short-term	NULL
cultures	NULL
of	NULL
human	NULL
leukemic	NULL
lymphoblasts	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
varying	NULL
concentrations	NULL
of	NULL
glucocorticoid	NULL
.	NULL

Unfortunately	NULL
,	NULL
these	NULL
experiments	NULL
could	NULL
not	NULL
be	NULL
accomplished	NULL
in	NULL
every	NULL
patient	NULL
.	NULL

However	NULL
,	NULL
in	NULL
patients	NULL
whose	NULL
cells	NULL
contained	NULL
binding	NULL
activity	NULL
there	NULL
was	NULL
a	NULL
close	NULL
correlation	NULL
between	NULL
concentrations	NULL
of	NULL
glucocorticoid	NULL
which	NULL
inhibited	NULL
nucleoside	NULL
incorporation	NULL
and	NULL
concentrations	NULL
which	NULL
bound	NULL
to	NULL
receptor	NULL
sites	NULL
(	NULL
19	NULL
,	NULL
20	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
never	NULL
observed	NULL
inhibition	NULL
of	NULL
nucleoside	NULL
incorporation	NULL
by	NULL
phar-macologically	NULL
relevant	NULL
concentrations	NULL
of	NULL
glucocorticoids	NULL
in	NULL
leukemic	NULL
blast	NULL
cells	NULL
from	NULL
patients	NULL
which	NULL
lacked	NULL
binding	NULL
activity	NULL
.	NULL

Surprisingly	NULL
,	NULL
we	NULL
never	NULL
failed	NULL
to	NULL
observe	NULL
inhibition	NULL
when	NULL
cytoplasmic	NULL
binding	NULL
was	NULL
present	NULL
.	NULL

This	NULL
was	NULL
an	NULL
unanticipated	NULL
result	NULL
,	NULL
given	NULL
the	NULL
many	NULL
steps	NULL
in	NULL
steroid	NULL
hormone	NULL
action	NULL
distal	NULL
to	NULL
the	NULL
initial	NULL
binding	NULL
reaction	NULL
(	NULL
35	NULL
)	NULL
which	NULL
potentially	NULL
might	NULL
be	NULL
interfered	NULL
with	NULL
and	NULL
yet	NULL
leave	NULL
behind	NULL
cytoplasmic	NULL
binding	NULL
activity	NULL
.	NULL

We	NULL
have	NULL
subsequently	NULL
described	NULL
a	NULL
human	NULL
ALL	NULL
cell	NULL
line	NULL
in	NULL
tissue	NULL
culture	NULL
in	NULL
which	NULL
although	NULL
there	NULL
is	NULL
cytoplasmic	NULL
binding	NULL
activity	NULL
,	NULL
there	NULL
are	NULL
no	NULL
demonstrable	NULL
biological	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
on	NULL
amino	NULL
acid	NULL
pools	NULL
,	NULL
glucose	NULL
uptake	NULL
,	NULL
macromolecular	NULL
synthe-sis	NULL
,	NULL
or	NULL
growth	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Subsequently	NULL
,	NULL
various	NULL
mouse	NULL
lymphoma	NULL
variants	NULL
or	NULL
mutants	NULL
derived	NULL
from	NULL
a	NULL
steroid-sensitive	NULL
mouse	NULL
lymphoma	NULL
line	NULL
(	NULL
$	NULL
49	NULL
)	NULL
have	NULL
been	NULL
extensively	NULL
characterized	NULL
by	NULL
several	NULL
workers	NULL
(	NULL
2	NULL
,	NULL
31	NULL
,	NULL
32	NULL
,	NULL
39	NULL
)	NULL
.	NULL

Most	NULL
of	NULL
the	NULL
glucocorticoid-resistant	NULL
clones	NULL
were	NULL
defective	NULL
in	NULL
binding	NULL
activity	NULL
,	NULL
and	NULL
in	NULL
all	NULL
of	NULL
the	NULL
remaining	NULL
clones	NULL
a	NULL
receptor	NULL
defect	NULL
could	NULL
also	NULL
be	NULL
invoked	NULL
as	NULL
a	NULL
potential	NULL
explanation	NULL
for	NULL
hormone	NULL
unre-sponsiveness	NULL
.	NULL

Whatever	NULL
the	NULL
explanation	NULL
for	NULL
the	NULL
common-ness	NULL
of	NULL
receptor	NULL
defects	NULL
in	NULL
glucocorticoid-resistant	NULL
leukemic	NULL
cells	NULL
,	NULL
it	NULL
is	NULL
nonetheless	NULL
quite	NULL
interesting	NULL
that	NULL
in	NULL
our	NULL
own	NULL
work	NULL
there	NULL
is	NULL
such	NULL
a	NULL
close	NULL
linkage	NULL
between	NULL
receptor	NULL
activity	NULL
and	NULL
clinical	NULL
responsiveness	NULL
,	NULL
not	NULL
only	NULL
to	NULL
glucocorticoids	NULL
in	NULL
vitro	NULL
but	NULL
also	NULL
drug	NULL
to	NULL
combinations	NULL
in	NULL
general	NULL
.	NULL

The	NULL
notion	NULL
that	NULL
glucocorticoid	NULL
binding	NULL
activity	NULL
might	NULL
be	NULL
important	NULL
in	NULL
predicting	NULL
response	NULL
to	NULL
other	NULL
cytotoxic	NULL
agents	NULL
is	NULL
suggested	NULL
by	NULL
these	NULL
data	NULL
and	NULL
will	NULL
receive	NULL
further	NULL
substantia-	NULL
CANCER	NULL
RESEARCH	NULL
VOL	NULL
.	NULL

38	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1978	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

tion	NULL
in	NULL
the	NULL
data	NULL
presented	NULL
below	NULL
.	NULL

Glucocorticoid	NULL
Receptors	NULL
in	NULL
Normal	NULL
Human	NULL
Lymphocytes	NULL
First	NULL
,	NULL
however	NULL
,	NULL
we	NULL
would	NULL
like	NULL
to	NULL
summarize	NULL
a	NULL
few	NULL
of	NULL
our	NULL
studies	NULL
which	NULL
characterize	NULL
the	NULL
glucocorticoid	NULL
receptors	NULL
of	NULL
normal	NULL
human	NULL
lymphocytes	NULL
(	NULL
18	NULL
,	NULL
27	NULL
)	NULL
.	NULL

We	NULL
had	NULL
originally	NULL
noted	NULL
(	NULL
19	NULL
)	NULL
that	NULL
lymphocytes	NULL
collected	NULL
from	NULL
normal	NULL
human	NULL
volunteers	NULL
appeared	NULL
to	NULL
have	NULL
very	NULL
low	NULL
levels	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
when	NULL
measured	NULL
by	NULL
a	NULL
cytoplasmic	NULL
assay	NULL
(	NULL
0.03	NULL
+	NULL
0.025	NULL
pmol	NULL
[	NULL
Â°H	NULL
}	NULL
dexamethasone	NULL
per	NULL
mg	NULL
cytoplasmic	NULL
protein	NULL
)	NULL
.	NULL

By	NULL
determining	NULL
cytoplasmic	NULL
protein	NULL
content	NULL
on	NULL
a	NULL
per-cell	NULL
basis	NULL
,	NULL
this	NULL
would	NULL
be	NULL
equivalent	NULL
to	NULL
about	NULL
1500	NULL
glucocorticoid	NULL
binding	NULL
sites/cell	NULL
.	NULL

For	NULL
a	NULL
variety	NULL
of	NULL
reasons	NULL
it	NULL
seemed	NULL
reasonable	NULL
to	NULL
repeat	NULL
and	NULL
extend	NULL
these	NULL
studies	NULL
to	NULL
purified	NULL
populations	NULL
and	NULL
subpopulations	NULL
of	NULL
human	NULL
lymphocytes	NULL
.	NULL

To	NULL
do	NULL
this	NULL
,	NULL
we	NULL
switched	NULL
to	NULL
a	NULL
whole	NULL
cell	NULL
assay	NULL
methodology	NULL
because	NULL
we	NULL
felt	NULL
that	NULL
this	NULL
assay	NULL
would	NULL
be	NULL
more	NULL
rapid	NULL
,	NULL
more	NULL
sensitive	NULL
,	NULL
and	NULL
might	NULL
allow	NULL
detection	NULL
of	NULL
binding	NULL
sites	NULL
which	NULL
were	NULL
noncytoplasmic	NULL
.	NULL

This	NULL
assay	NULL
has	NULL
been	NULL
extensively	NULL
validated	NULL
(	NULL
15	NULL
)	NULL
.	NULL

With	NULL
the	NULL
use	NULL
of	NULL
such	NULL
a	NULL
methodology	NULL
,	NULL
glucocorticoid	NULL
receptor	NULL
activity	NULL
is	NULL
readily	NULL
demonstrable	NULL
in	NULL
normal	NULL
human	NULL
lymphocytes	NULL
essentially	NULL
free	NULL
of	NULL
polymorphonuciear	NULL
leukocyte	NULL
and	NULL
other	NULL
mononuclear	NULL
cell	NULL
contamination	NULL
(	NULL
greater	NULL
than	NULL
99.5	NULL
%	NULL
small	NULL
lymphocytes	NULL
)	NULL
.	NULL

Homo	NULL
and	NULL
colleagues	NULL
(	NULL
11	NULL
)	NULL
,	NULL
using	NULL
a	NULL
similar	NULL
assay	NULL
,	NULL
have	NULL
also	NULL
been	NULL
able	NULL
to	NULL
demonstrate	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
normal	NULL
human	NULL
lymphocytes	NULL
.	NULL

They	NULL
used	NULL
a	NULL
Ficoll-Hypaque	NULL
technique	NULL
(	NULL
4	NULL
)	NULL
to	NULL
separate	NULL
mononuclear	NULL
cells	NULL
;	NULL
however	NULL
,	NULL
such	NULL
preparations	NULL
contain	NULL
significant	NULL
amounts	NULL
(	NULL
up	NULL
to	NULL
10	NULL
%	NULL
)	NULL
of	NULL
monocytes	NULL
.	NULL

As	NULL
described	NULL
later	NULL
,	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
these	NULL
monocytes	NULL
contain	NULL
more	NULL
than	NULL
7000	NULL
glucocorticoid	NULL
receptor	NULL
sites/cell	NULL
(	NULL
18	NULL
)	NULL
.	NULL

We	NULL
found	NULL
that	NULL
small	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
contain	NULL
about	NULL
2300	NULL
glucocorticoid	NULL
sites/cell	NULL
which	NULL
,	NULL
in	NULL
terms	NULL
of	NULL
affinity	NULL
for	NULL
[	NULL
*H	NULL
}	NULL
dexamethasone	NULL
(	NULL
K	NULL
,	NULL
,	NULL
2	NULL
to	NULL
4	NULL
nm	NULL
)	NULL
and	NULL
specificity	NULL
studies	NULL
,	NULL
are	NULL
perfectly	NULL
typical	NULL
of	NULL
other	NULL
glucocorticoid	NULL
receptors	NULL
.	NULL

When	NULL
these	NULL
cells	NULL
are	NULL
stimulated	NULL
with	NULL
the	NULL
mitogen	NULL
phytohemagglutinin	NULL
,	NULL
there	NULL
is	NULL
about	NULL
a	NULL
3-fold	NULL
increase	NULL
in	NULL
glucocorticoid	NULL
receptor	NULL
activity	NULL
on	NULL
a	NULL
per-cell	NULL
basis	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Induction	NULL
occurs	NULL
after	NULL
about	NULL
a	NULL
10-	NULL
to	NULL
12-hr	NULL
lag	NULL
.	NULL

This	NULL
induction	NULL
of	NULL
glucocorticoid	NULL
binding	NULL
activity	NULL
can	NULL
be	NULL
totally	NULL
inhibited	NULL
by	NULL
concurrent	NULL
incubation	NULL
with	NULL
either	NULL
actinomycin	NULL
D	NULL
or	NULL
cycioheximide	NULL
.	NULL

These	NULL
studies	NULL
have	NULL
been	NULL
confirmed	NULL
by	NULL
others	NULL
(	NULL
33	NULL
)	NULL
.	NULL

While	NULL
both	NULL
``	NULL
resting	NULL
``	NULL
and	NULL
lectin-stimulated	NULL
lymphocytes	NULL
can	NULL
be	NULL
inhibited	NULL
by	NULL
glucocorticoids	NULL
,	NULL
the	NULL
degree	NULL
of	NULL
inhibition	NULL
is	NULL
far	NULL
higher	NULL
in	NULL
the	NULL
stimulated	NULL
cells	NULL
;	NULL
however	NULL
,	NULL
when	NULL
measured	NULL
relatively	NULL
crudely	NULL
,	NULL
the	NULL
sensitivity	NULL
to	NULL
hormone	NULL
is	NULL
unaltered	NULL
.	NULL

However	NULL
,	NULL
one	NULL
might	NULL
predict	NULL
that	NULL
when	NULL
a	NULL
given	NULL
biological	NULL
effect	NULL
depends	NULL
upon	NULL
the	NULL
quantity	NULL
of	NULL
hormone	NULL
receptor	NULL
complex	NULL
which	NULL
is	NULL
formed	NULL
,	NULL
rather	NULL
than	NULL
for	NULL
any	NULL
given	NULL
ambient	NULL
hormone	NULL
concentration	NULL
,	NULL
the	NULL
cell	NULL
with	NULL
the	NULL
highest	NULL
receptor	NULL
concentration	NULL
would	NULL
have	NULL
the	NULL
highest	NULL
concentration	NULL
of	NULL
hormone	NULL
receptor	NULL
complexes	NULL
,	NULL
other	NULL
factors	NULL
being	NULL
equal	NULL
.	NULL

Thus	NULL
cells	NULL
with	NULL
higher	NULL
receptor	NULL
concentrations	NULL
might	NULL
be	NULL
differentially	NULL
more	NULL
sensitive	NULL
to	NULL
glucocorticoids	NULL
.	NULL

Elsewhere	NULL
in	NULL
this	NULL
symposium	NULL
,	NULL
a	NULL
report	NULL
from	NULL
the	NULL
laboratory	NULL
of	NULL
Bourgeois	NULL
et	NULL
al	NULL
.	NULL

(	NULL
3	NULL
)	NULL
elegantly	NULL
confirms	NULL
this	NULL
hypothesis	NULL
.	NULL

These	NULL
increases	NULL
in	NULL
receptor	NULL
have	NULL
been	NULL
suggested	NULL
to	NULL
be	NULL
due	NULL
to	NULL
variations	NULL
in	NULL
receptor	NULL
content	NULL
with	NULL
different	NULL
phases	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

Cidlowski	NULL
and	NULL
Michaels	NULL
(	NULL
5	NULL
)	NULL
have	NULL
suggested	NULL
that	NULL
in	NULL
synchronized	NULL
HeLa	NULL
cells	NULL
in	NULL
NOVEMBER	NULL
1978	NULL
Glucocorticoid	NULL
Receptors	NULL
and	NULL
Leukemia	NULL
culture	NULL
there	NULL
is	NULL
a	NULL
doubling	NULL
of	NULL
the	NULL
receptor	NULL
content	NULL
on	NULL
a	NULL
per-cell	NULL
basis	NULL
as	NULL
the	NULL
cells	NULL
pass	NULL
through	NULL
late	NULL
G	NULL
,	NULL
.	NULL

In	NULL
our	NULL
studies	NULL
,	NULL
phytohemagglutinin	NULL
stimulates	NULL
an	NULL
increase	NULL
in	NULL
glucocorticoid	NULL
receptor	NULL
activity	NULL
occurring	NULL
between	NULL
14	NULL
and	NULL
20	NULL
hr	NULL
,	NULL
which	NULL
is	NULL
well	NULL
in	NULL
advance	NULL
of	NULL
the	NULL
entrance	NULL
of	NULL
these	NULL
cells	NULL
into	NULL
the	NULL
DNA-synthetic	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
(	NULL
36	NULL
)	NULL
.	NULL

These	NULL
purified	NULL
lymphocytes	NULL
consist	NULL
of	NULL
about	NULL
65	NULL
to	NULL
75	NULL
%	NULL
T-cells	NULL
and	NULL
20	NULL
to	NULL
30	NULL
%	NULL
B-cells	NULL
.	NULL

We	NULL
have	NULL
recently	NULL
attempted	NULL
to	NULL
further	NULL
characterize	NULL
subpopulations	NULL
of	NULL
normal	NULL
human	NULL
lymphocytes	NULL
for	NULL
2	NULL
reasons	NULL
(	NULL
first	NULL
,	NULL
because	NULL
of	NULL
the	NULL
known	NULL
differential	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
on	NULL
different	NULL
limbs	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
(	NULL
9	NULL
)	NULL
and	NULL
,	NULL
secondly	NULL
,	NULL
as	NULL
an	NULL
attempt	NULL
to	NULL
explain	NULL
differences	NULL
in	NULL
receptor	NULL
content	NULL
in	NULL
various	NULL
subsets	NULL
of	NULL
human	NULL
leukemic	NULL
blast	NULL
cells	NULL
)	NULL
.	NULL

With	NULL
the	NULL
use	NULL
of	NULL
rosetting	NULL
techniques	NULL
,	NULL
highly	NULL
purified	NULL
populations	NULL
of	NULL
T-	NULL
,	NULL
non-T-	NULL
,	NULL
and	NULL
mononuclear	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
human	NULL
peripheral	NULL
blood	NULL
,	NULL
and	NULL
glucocorticoid	NULL
binding	NULL
activity	NULL
was	NULL
determined	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Results	NULL
are	NULL
shown	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

There	NULL
is	NULL
no	NULL
difference	NULL
in	NULL
either	NULL
T-	NULL
or	NULL
non-T-receptor	NULL
content	NULL
on	NULL
a	NULL
per-cell	NULL
basis	NULL
or	NULL
in	NULL
affinity	NULL
for	NULL
glucocorticoid	NULL
.	NULL

Specificity	NULL
of	NULL
the	NULL
binding	NULL
site	NULL
for	NULL
various	NULL
steroids	NULL
was	NULL
very	NULL
similar	NULL
as	NULL
well	NULL
.	NULL

Mononuclear	NULL
cells	NULL
had	NULL
about	NULL
7,000	NULL
sites/	NULL
cell	NULL
.	NULL

Nonstimulated	NULL
T-	NULL
and	NULL
non-T-populations	NULL
of	NULL
human	NULL
lymphocytes	NULL
showed	NULL
an	NULL
approximately	NULL
equal	NULL
degree	NULL
of	NULL
inhibition	NULL
by	NULL
glucocorticoids	NULL
when	NULL
overall	NULL
precursor	NULL
incorporation	NULL
into	NULL
macromolecules	NULL
was	NULL
measured	NULL
.	NULL

Interference	NULL
with	NULL
specific	NULL
immune	NULL
function	NULL
such	NULL
as	NULL
performance	NULL
in	NULL
cytotoxicity	NULL
assays	NULL
or	NULL
immunoglobulin	NULL
production	NULL
was	NULL
not	NULL
measured	NULL
.	NULL

Our	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
differential	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
on	NULL
the	NULL
immune	NULL
system	NULL
do	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
mediated	NULL
by	NULL
differences	NULL
in	NULL
glucocorticoid	NULL
receptor	NULL
content	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

Glucocorticoid	NULL
Receptors	NULL
in	NULL
Subsets	NULL
of	NULL
Human	NULL
ALL	NULL
Recently	NULL
,	NULL
we	NULL
have	NULL
reexamined	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
ALL	NULL
and	NULL
attempted	NULL
to	NULL
correlate	NULL
glucocorticoid	NULL
receptor	NULL
levels	NULL
with	NULL
different	NULL
cell	NULL
subpopulations	NULL
(	NULL
14	NULL
,	NULL
15	NULL
)	NULL
.	NULL

Approximately	NULL
one-fifth	NULL
of	NULL
patients	NULL
with	NULL
ALL	NULL
have	NULL
lymphoblasts	NULL
which	NULL
will	NULL
form	NULL
spontaneous	NULL
rosettes	NULL
with	NULL
sheep	NULL
erythrocytes	NULL
and	NULL
are	NULL
therefore	NULL
termed	NULL
T-derived	NULL
lymphoblasts	NULL
.	NULL

These	NULL
patients	NULL
will	NULL
have	NULL
a	NULL
disease	NULL
which	NULL
frequently	NULL
presents	NULL
differently	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
mediastinal	NULL
masses	NULL
)	NULL
and	NULL
which	NULL
is	NULL
more	NULL
aggressive	NULL
in	NULL
that	NULL
there	NULL
are	NULL
very	NULL
few	NULL
long-term	NULL
survivors	NULL
(	NULL
12	NULL
,	NULL
30	NULL
,	NULL
37	NULL
)	NULL
.	NULL

The	NULL
majority	NULL
of	NULL
patients	NULL
have	NULL
lymphoblasts	NULL
which	NULL
lack	NULL
identifiable	NULL
cell	NULL
surface	NULL
markers	NULL
(	NULL
termed	NULL
null	NULL
cells	NULL
)	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
lymphoblasts	NULL
that	NULL
make	NULL
E-rosettes	NULL
usually	NULL
share	NULL
with	NULL
normal	NULL
human	NULL
E-ro-sette-forming	NULL
cells	NULL
the	NULL
inability	NULL
to	NULL
stimulate	NULL
allogeneic	NULL
re-sponders	NULL
in	NULL
the	NULL
mixed-lymphocyte	NULL
culture	NULL
.	NULL

We	NULL
have	NULL
postulated	NULL
that	NULL
the	NULL
inability	NULL
or	NULL
loss	NULL
of	NULL
ability	NULL
to	NULL
stimulate	NULL
in	NULL
mixed-lymphocyte	NULL
culture	NULL
may	NULL
represent	NULL
maturation	NULL
along	NULL
Table	NULL
1	NULL
Glucocorticoid	NULL
receptors	NULL
in	NULL
subpopulations	NULL
of	NULL
human	NULL
leukocytes	NULL
No	NULL
.	NULL

of	NULL
_	NULL
Glucocorticoid	NULL
-	NULL
Dissocia-experi-	NULL
_	NULL
receptor	NULL
levels	NULL
tion	NULL
con-ments	NULL
{	NULL
sites/cell	NULL
)	NULL
stant	NULL
(	NULL
nM	NULL
)	NULL
T-lymphocytes	NULL
5	NULL
3130	NULL
+	NULL
1316	NULL
3.5	NULL
+	NULL
1.4	NULL
Non-T-lymphocytes	NULL
4	NULL
2892	NULL
+	NULL
1068	NULL
4.0	NULL
+	NULL
1.7	NULL
Monocytes	NULL
2	NULL
7009	NULL
+	NULL
1455	NULL
5.1	NULL
4253	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1978	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

M.	NULL
E.	NULL
Lippman	NULL
et	NULL
al	NULL
.	NULL

the	NULL
pathway	NULL
of	NULL
T-cell	NULL
differentiation	NULL
.	NULL

We	NULL
therefore	NULL
subdivide	NULL
null	NULL
lymphoblasts	NULL
into	NULL
2	NULL
categories	NULL
,	NULL
according	NULL
to	NULL
whether	NULL
or	NULL
not	NULL
they	NULL
stimulate	NULL
in	NULL
mixed-lymphocyte	NULL
culture	NULL
,	NULL
for	NULL
the	NULL
purpose	NULL
of	NULL
analysis	NULL
in	NULL
this	NULL
paper	NULL
.	NULL

We	NULL
have	NULL
compared	NULL
glucocorticoid	NULL
receptor	NULL
levels	NULL
in	NULL
these	NULL
subtypes	NULL
of	NULL
ALL	NULL
and	NULL
have	NULL
determined	NULL
their	NULL
relationship	NULL
to	NULL
other	NULL
prognostic	NULL
variables	NULL
in	NULL
these	NULL
patients	NULL
.	NULL

Glucocorticoid	NULL
receptors	NULL
are	NULL
readily	NULL
detectable	NULL
in	NULL
T-	NULL
and	NULL
null	NULL
leukemic	NULL
cells	NULL
.	NULL

By	NULL
either	NULL
affinity	NULL
criteria	NULL
(	NULL
K	NULL
,	NULL
~	NULL
4	NULL
nm	NULL
for	NULL
[	NULL
Â°H	NULL
]	NULL
dexamethasone	NULL
)	NULL
or	NULL
binding	NULL
specificity	NULL
studies	NULL
,	NULL
T-	NULL
and	NULL
null	NULL
cell	NULL
leukemic	NULL
cells	NULL
are	NULL
indis-tinguishable	NULL
.	NULL

However	NULL
,	NULL
there	NULL
are	NULL
significant	NULL
differences	NULL
in	NULL
receptor	NULL
content	NULL
between	NULL
these	NULL
cells	NULL
.	NULL

Null	NULL
cells	NULL
from	NULL
18	NULL
patients	NULL
which	NULL
stimulate	NULL
in	NULL
mixed-lymphocyte	NULL
culture	NULL
(	NULL
N+	NULL
)	NULL
have	NULL
a	NULL
median	NULL
receptor	NULL
content	NULL
of	NULL
7,571	NULL
sites/cell	NULL
,	NULL
a	NULL
mean	NULL
of	NULL
10,117	NULL
,	NULL
and	NULL
a	NULL
range	NULL
of	NULL
4,096	NULL
to	NULL
21,869	NULL
sites/cell	NULL
.	NULL

Nine	NULL
patients	NULL
had	NULL
null	NULL
cells	NULL
which	NULL
did	NULL
not	NULL
stimulate	NULL
in	NULL
mixed-lymphocyte	NULL
culture	NULL
(	NULL
N-	NULL
)	NULL
.	NULL

Cells	NULL
of	NULL
these	NULL
patients	NULL
had	NULL
a	NULL
median	NULL
of	NULL
4,484	NULL
sites/cell	NULL
,	NULL
with	NULL
a	NULL
mean	NULL
of	NULL
6,729	NULL
and	NULL
a	NULL
range	NULL
of	NULL
2,936	NULL
to	NULL
16,469	NULL
.	NULL

Nine	NULL
patients	NULL
whose	NULL
T-lymphoblasts	NULL
were	NULL
studied	NULL
had	NULL
a	NULL
median	NULL
of	NULL
2,173	NULL
sites/cell	NULL
,	NULL
a	NULL
mean	NULL
of	NULL
2,538	NULL
and	NULL
a	NULL
range	NULL
of	NULL
0	NULL
to	NULL
5,887	NULL
.	NULL

T-lymphoblasts	NULL
differ	NULL
significantly	NULL
by	NULL
2-tailed	NULL
test	NULL
from	NULL
N+	NULL
lymphoblasts	NULL
(	NULL
p	NULL
<	NULL
0.001	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
N-	NULL
lymphoblasts	NULL
(	NULL
p	NULL
<	NULL
0.01	NULL
)	NULL
.	NULL

Some	NULL
important	NULL
patient	NULL
characteristics	NULL
as	NULL
a	NULL
function	NULL
of	NULL
receptor	NULL
content	NULL
are	NULL
shown	NULL
in	NULL
Table	NULL
2	NULL
.	NULL

Cells	NULL
from	NULL
a	NULL
total	NULL
of	NULL
45	NULL
patients	NULL
eventually	NULL
were	NULL
examined	NULL
for	NULL
cell	NULL
surface	NULL
markers	NULL
and	NULL
glucocorticoid	NULL
receptor	NULL
content	NULL
,	NULL
and	NULL
these	NULL
data	NULL
were	NULL
collated	NULL
with	NULL
clinical	NULL
information	NULL
from	NULL
these	NULL
patients	NULL
.	NULL

Eleven	NULL
patients	NULL
with	NULL
low	NULL
levels	NULL
of	NULL
receptor	NULL
(	NULL
less	NULL
than	NULL
2,500	NULL
sites/cell	NULL
)	NULL
all	NULL
had	NULL
T-lymphoblasts	NULL
.	NULL

Seven	NULL
patients	NULL
with	NULL
T-	NULL
and	NULL
11	NULL
with	NULL
null	NULL
|ymphobilasts	NULL
had	NULL
intermediate	NULL
receptor	NULL
levels	NULL
of	NULL
greater	NULL
than	NULL
2,500	NULL
,	NULL
but	NULL
less	NULL
than	NULL
6,000	NULL
,	NULL
sites/cell	NULL
.	NULL

Sixteen	NULL
patients	NULL
with	NULL
high	NULL
receptor	NULL
levels	NULL
(	NULL
greater	NULL
than	NULL
6,000	NULL
sites/cell	NULL
)	NULL
had	NULL
null	NULL
lymphoblasts	NULL
.	NULL

Patients	NULL
with	NULL
T-cell	NULL
leukemia	NULL
tend	NULL
to	NULL
be	NULL
older	NULL
,	NULL
as	NULL
has	NULL
been	NULL
previously	NULL
shown	NULL
.	NULL

Patients	NULL
with	NULL
T-cell	NULL
ALL	NULL
with	NULL
lower	NULL
receptor	NULL
levels	NULL
had	NULL
higher	NULL
WBC	NULL
than	NULL
did	NULL
patients	NULL
with	NULL
the	NULL
same	NULL
cell	NULL
type	NULL
who	NULL
had	NULL
higher	NULL
receptor	NULL
levels	NULL
.	NULL

We	NULL
next	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
receptor	NULL
level	NULL
on	NULL
initial	NULL
complete	NULL
remission	NULL
induction	NULL
and	NULL
duration	NULL
.	NULL

Chart	NULL
1	NULL
shows	NULL
the	NULL
results	NULL
for	NULL
patients	NULL
with	NULL
T-lymphoblasts	NULL
.	NULL

Eleven	NULL
patients	NULL
had	NULL
less	NULL
than	NULL
2,500	NULL
receptor	NULL
sites/cell	NULL
,	NULL
and	NULL
7	NULL
patients	NULL
had	NULL
between	NULL
2,500	NULL
and	NULL
6,000	NULL
sites/cell	NULL
.	NULL

Two	NULL
patients	NULL
in	NULL
each	NULL
group	NULL
failed	NULL
to	NULL
achieve	NULL
a	NULL
complete	NULL
remission	NULL
.	NULL

While	NULL
curves	NULL
for	NULL
remission	NULL
duration	NULL
are	NULL
not	NULL
quite	NULL
significantly	NULL
different	NULL
(	NULL
0.05	NULL
<	NULL
p	NULL
<	NULL
0.1	NULL
)	NULL
when	NULL
only	NULL
patients	NULL
achieving	NULL
complete	NULL
remission	NULL
are	NULL
considered	NULL
,	NULL
the	NULL
2	NULL
groups	NULL
are	NULL
significantly	NULL
different	NULL
with	NULL
respect	NULL
to	NULL
complete	NULL
remission	NULL
duration	NULL
.	NULL

All	NULL
11	NULL
patients	NULL
with	NULL
low	NULL
receptor	NULL
levels	NULL
have	NULL
relapsed	NULL
,	NULL
while	NULL
3	NULL
to	NULL
7	NULL
patients	NULL
with	NULL
intermediate	NULL
receptor	NULL
levels	NULL
remain	NULL
in	NULL
remission	NULL
.	NULL

Table	NULL
2	NULL
Patient	NULL
characteristics	NULL
in	NULL
childhood	NULL
ALL	NULL
Age	NULL
WBC	NULL
Receptor	NULL
level	NULL
Cell	NULL
No	NULL
.	NULL

of	NULL
(	NULL
median	NULL
_	NULL
Sex	NULL
(	NULL
me-	NULL
(	NULL
sites/cell	NULL
)	NULL
type	NULL
-	NULL
patients	NULL
|	NULL
in	NULL
yr	NULL
)	NULL
(	NULL
M/F	NULL
)	NULL
dian	NULL
)	NULL
<	NULL
2,500	NULL
T	NULL
11	NULL
13.8	NULL
9/2	NULL
49,000	NULL
2,501	NULL
to	NULL
<	NULL
6,000	NULL
T	NULL
7	NULL
11	NULL
5/2	NULL
7,600	NULL
2,501	NULL
to	NULL
<	NULL
6,000	NULL
Null	NULL
11	NULL
7.6	NULL
9/2	NULL
17,200	NULL
>	NULL
6,000	NULL
Null	NULL
16	NULL
7.3	NULL
7/9	NULL
17,000	NULL
4254	NULL
Chart	NULL
2	NULL
provides	NULL
a	NULL
similar	NULL
analysis	NULL
of	NULL
complete	NULL
remission	NULL
duration	NULL
for	NULL
patients	NULL
with	NULL
null-cell	NULL
disease	NULL
.	NULL

As	NULL
shown	NULL
,	NULL
null-cell	NULL
patients	NULL
with	NULL
high	NULL
levels	NULL
of	NULL
receptor	NULL
do	NULL
significantly	NULL
better	NULL
(	NULL
p	NULL
<	NULL
0.02	NULL
)	NULL
than	NULL
patients	NULL
with	NULL
intermediate	NULL
receptor	NULL
values	NULL
.	NULL

If	NULL
Charts	NULL
1	NULL
and	NULL
2	NULL
are	NULL
compared	NULL
,	NULL
it	NULL
can	NULL
be	NULL
seen	NULL
that	NULL
the	NULL
curves	NULL
for	NULL
either	NULL
T-	NULL
or	NULL
null-cell	NULL
patients	NULL
with	NULL
intermediate	NULL
levels	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
are	NULL
virtually	NULL
superimposa-ble	NULL
.	NULL

Independent	NULL
of	NULL
cell	NULL
type	NULL
,	NULL
glucocorticoid	NULL
receptor	NULL
level	NULL
was	NULL
strongly	NULL
correlated	NULL
with	NULL
remission	NULL
duration	NULL
.	NULL

Results	NULL
are	NULL
shown	NULL
in	NULL
Chart	NULL
3	NULL
.	NULL

Eleven	NULL
patients	NULL
with	NULL
receptor	NULL
levels	NULL
of	NULL
0	NULL
to	NULL
2,500	NULL
sites/cell	NULL
had	NULL
a	NULL
median	NULL
complete	NULL
remission	NULL
duration	NULL
of	NULL
7.6	NULL
months	NULL
.	NULL

The	NULL
relative	NULL
relapse	NULL
rate	NULL
when	NULL
compared	NULL
to	NULL
the	NULL
combined	NULL
groups	NULL
is	NULL
2.76	NULL
,	NULL
and	NULL
all	NULL
11	NULL
patients	NULL
have	NULL
relapsed	NULL
.	NULL

Eighteen	NULL
patients	NULL
with	NULL
intermediate	NULL
receptor	NULL
levels	NULL
(	NULL
7	NULL
T	NULL
and	NULL
11	NULL
null	NULL
)	NULL
had	NULL
a	NULL
median	NULL
remission	NULL
duration	NULL
of	NULL
21.4	NULL
months	NULL
.	NULL

The	NULL
relative	NULL
relapse	NULL
rate	NULL
of	NULL
these	NULL
patients	NULL
is	NULL
1.1	NULL
.	NULL

Sixteen	NULL
patients	NULL
(	NULL
all	NULL
null-cell	NULL
type	NULL
)	NULL
with	NULL
high	NULL
receptor	NULL
levels	NULL
have	NULL
a	NULL
median	NULL
remission	NULL
duration	NULL
in	NULL
excess	NULL
of	NULL
30.4	NULL
months	NULL
.	NULL

The	NULL
relative	NULL
relapse	NULL
rate	NULL
is	NULL
0.42	NULL
.	NULL

Each	NULL
of	NULL
so	NULL
P.	NULL
~	NULL
i	NULL
\	NULL
:	NULL
F1	NULL
H	NULL
Â©	NULL
ao	NULL
|-	NULL
R	NULL
n	NULL
&	NULL
E	NULL
&	NULL
3	NULL
|	NULL
3	NULL
a	NULL
e	NULL
a	NULL
[	NULL
-	NULL
f	NULL
?	NULL

z	NULL
&	NULL
1	NULL
â‚¬	NULL
L	NULL
&	NULL
\	NULL
a	NULL
|-	NULL
1	NULL
\\	NULL
A\\	NULL
<	NULL
_	NULL
L100	NULL
L2	NULL
Crn	NULL
(	NULL
200	NULL
02200	NULL
2a	NULL
2222	NULL
0	NULL
12	NULL
24	NULL
36	NULL
a8	NULL
60	NULL
72	NULL
REMISSION	NULL
DURATION	NULL
monins	NULL
Chart	NULL
1	NULL
.	NULL

Complete	NULL
remission	NULL
duration	NULL
in	NULL
patients	NULL
with	NULL
T-cell-type	NULL
ALL	NULL
.	NULL

A	NULL
,	NULL
patients	NULL
with	NULL
receptor	NULL
levels	NULL
<	NULL
2500	NULL
glucocorticoid	NULL
sites/cell	NULL
;	NULL
Â®	NULL
,	NULL
patients	NULL
with	NULL
receptor	NULL
levels	NULL
between	NULL
2500	NULL
and	NULL
6000	NULL
glucocorticoid	NULL
sites/cell	NULL
;	NULL
x	NULL
,	NULL
patients	NULL
still	NULL
in	NULL
remission	NULL
.	NULL

PERCENT	NULL
:	NULL
IN	NULL
COMPLETE	NULL
:	NULL
REMISSION	NULL
[	NULL
nono	NULL
e	NULL
eg	NULL
o	NULL
12	NULL
24	NULL
%	NULL
as	NULL
so	NULL
0	NULL
==	NULL
r	NULL
REMISSION	NULL
DURATION	NULL
:	NULL
imontns	NULL
!	NULL

Chart	NULL
2	NULL
.	NULL

Complete	NULL
remission	NULL
duration	NULL
in	NULL
patients	NULL
with	NULL
null-cell-type	NULL
ALL	NULL
.	NULL

@	NULL
,	NULL
patients	NULL
with	NULL
receptor	NULL
levels	NULL
between	NULL
2500	NULL
and	NULL
6000	NULL
glucocorticoid	NULL
sites/	NULL
cell	NULL
;	NULL
O	NULL
,	NULL
patients	NULL
with	NULL
receptor	NULL
levels	NULL
>	NULL
6000	NULL
glucocorticoid	NULL
sites/cell	NULL
;	NULL
x	NULL
,	NULL
patients	NULL
still	NULL
in	NULL
remission	NULL
.	NULL

CANCER	NULL
RESEARCH	NULL
VOL	NULL
.	NULL

38	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1978	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

these	NULL
curves	NULL
is	NULL
significantly	NULL
different	NULL
from	NULL
the	NULL
other	NULL
,	NULL
and	NULL
the	NULL
difference	NULL
in	NULL
the	NULL
3	NULL
groups	NULL
compared	NULL
together	NULL
is	NULL
highly	NULL
significant	NULL
(	NULL
p	NULL
<	NULL
0.001	NULL
)	NULL
with	NULL
the	NULL
use	NULL
of	NULL
the	NULL
y	NULL
?	NULL

test	NULL
for	NULL
trend	NULL
.	NULL

High	NULL
WBC	NULL
at	NULL
the	NULL
time	NULL
of	NULL
initial	NULL
presentation	NULL
is	NULL
well	NULL
correlated	NULL
with	NULL
a	NULL
poor	NULL
prognosis	NULL
in	NULL
ALL	NULL
.	NULL

For	NULL
this	NULL
reason	NULL
we	NULL
examined	NULL
remission	NULL
duration	NULL
and	NULL
survival	NULL
for	NULL
the	NULL
21	NULL
patients	NULL
with	NULL
initial	NULL
WBC	NULL
in	NULL
excess	NULL
of	NULL
20,000	NULL
.	NULL

Effects	NULL
of	NULL
receptor	NULL
level	NULL
on	NULL
remission	NULL
duration	NULL
for	NULL
this	NULL
subset	NULL
of	NULL
patients	NULL
are	NULL
shown	NULL
in	NULL
Chart	NULL
4	NULL
.	NULL

For	NULL
either	NULL
T-	NULL
or	NULL
null-cell	NULL
patients	NULL
with	NULL
blasts	NULL
with	NULL
less	NULL
than	NULL
6,000	NULL
sites/cell	NULL
,	NULL
the	NULL
median	NULL
remission	NULL
duration	NULL
was	NULL
8	NULL
months	NULL
,	NULL
and	NULL
all	NULL
patients	NULL
have	NULL
relapsed	NULL
.	NULL

For	NULL
the	NULL
7	NULL
patients	NULL
with	NULL
blasts	NULL
with	NULL
greater	NULL
than	NULL
6,000	NULL
sites/cell	NULL
(	NULL
all	NULL
null	NULL
)	NULL
,	NULL
the	NULL
median	NULL
remission	NULL
duration	NULL
is	NULL
25	NULL
months	NULL
,	NULL
and	NULL
3	NULL
of	NULL
7	NULL
remain	NULL
in	NULL
remission	NULL
at	NULL
31	NULL
,	NULL
66	NULL
,	NULL
and	NULL
74	NULL
months	NULL
,	NULL
respectively	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
2	NULL
null-cell	NULL
groups	NULL
are	NULL
equivalent	NULL
with	NULL
respect	NULL
to	NULL
age	NULL
and	NULL
WBC	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
only	NULL
identified	NULL
difference	NULL
between	NULL
them	NULL
is	NULL
their	NULL
receptor	NULL
level	NULL
.	NULL

Survival	NULL
for	NULL
this	NULL
subset	NULL
of	NULL
patients	NULL
with	NULL
high	NULL
initial	NULL
WBC	NULL
is	NULL
shown	NULL
in	NULL
Table	NULL
3	NULL
.	NULL

As	NULL
shown	NULL
,	NULL
T-	NULL
and	NULL
null-cell	NULL
patients	NULL
with	NULL
190	NULL
\	NULL
bo	NULL
so	NULL
Q\\	NULL
\	NULL
&	NULL
``	NULL
|	NULL
~~	NULL
~	NULL
9	NULL
\	NULL
%	NULL
<	NULL
2	NULL
I	NULL
{	NULL
%	NULL
\\	NULL
a	NULL
L	NULL
\	NULL
\	NULL
&	NULL
so	NULL
!	NULL

-r	NULL
--	NULL
e	NULL
--	NULL
-+	NULL
Â§0	NULL
}	NULL
+	NULL
A	NULL
g	NULL
1	NULL
\	NULL
8	NULL
1	NULL
*	NULL
&	NULL
Â°	NULL
I	NULL
x	NULL
5	NULL
1	NULL
Ru	NULL
,	NULL
&	NULL
|	NULL
.	NULL

~~	NULL
i	NULL
t	NULL
Nx	NULL
Eo	NULL
.	NULL

\	NULL
Nerses	NULL
--	NULL
a	NULL
Â®	NULL
:	NULL
-	NULL
%	NULL
{	NULL
\	NULL
R	NULL
m	NULL
+	NULL
*~	NULL
_	NULL
L_	NULL
~a	NULL
ul	NULL
1	NULL
i	NULL
0	NULL
12	NULL
F	NULL
3	NULL
Â«	NULL
s	NULL
so	NULL
72	NULL
REMISSION	NULL
DURATION	NULL
:	NULL
imonths	NULL
?	NULL

Chart	NULL
3	NULL
.	NULL

Complete	NULL
remission	NULL
duration	NULL
in	NULL
patients	NULL
with	NULL
ALL	NULL
as	NULL
a	NULL
function	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
levels	NULL
.	NULL

A	NULL
,	NULL
patients	NULL
with	NULL
receptor	NULL
levels	NULL
<	NULL
2500	NULL
glucocorticoid	NULL
sites/cell	NULL
;	NULL
@	NULL
,	NULL
patients	NULL
with	NULL
receptor	NULL
levels	NULL
between	NULL
2500	NULL
and	NULL
6000	NULL
glucocorticoid	NULL
sites/cell	NULL
;	NULL
O	NULL
,	NULL
patients	NULL
with	NULL
receptor	NULL
levels	NULL
>	NULL
6000	NULL
glucocorticoid	NULL
sites/cell	NULL
;	NULL
x	NULL
,	NULL
patients	NULL
still	NULL
in	NULL
remission	NULL
.	NULL

PERCENT	NULL
SURVIVING	NULL
see	NULL
L	NULL
%	NULL
Sl	NULL
Cl	NULL
1	NULL
SURVIVAL	NULL
-	NULL
{	NULL
months	NULL
)	NULL
Chart	NULL
4	NULL
.	NULL

Complete	NULL
remission	NULL
duration	NULL
in	NULL
patients	NULL
with	NULL
ALL	NULL
and	NULL
initial	NULL
WBC	NULL
above	NULL
20,000	NULL
cells/Cu	NULL
mm	NULL
.	NULL

Â®	NULL
,	NULL
T-cell	NULL
patients	NULL
with	NULL
<	NULL
6000	NULL
glucocorticoid	NULL
sites/cell	NULL
;	NULL
A	NULL
,	NULL
null-cell	NULL
patients	NULL
with	NULL
<	NULL
6000	NULL
glucocorticoid	NULL
sites/cell	NULL
;	NULL
O	NULL
,	NULL
null-cell	NULL
patients	NULL
with	NULL
>	NULL
6000	NULL
glucocorticoid	NULL
sites/cell	NULL
;	NULL
x	NULL
,	NULL
patients	NULL
still	NULL
in	NULL
remission	NULL
.	NULL

NOVEMBER	NULL
1978	NULL
Glucocorticoid	NULL
Receptors	NULL
and	NULL
Leukemia	NULL
Table	NULL
3	NULL
Survival	NULL
and	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
``	NULL
poor	NULL
prognosis	NULL
``	NULL
ALL	NULL
(	NULL
WBC	NULL
>	NULL
20,000	NULL
)	NULL
Receptor	NULL
levels	NULL
Median	NULL
sur-	NULL
Proportion	NULL
(	NULL
sites/cell	NULL
)	NULL
Cell	NULL
type	NULL
vival	NULL
(	NULL
mos	NULL
.	NULL
)	NULL

alive	NULL
<	NULL
6,000	NULL
T	NULL
19.0	NULL
1/9	NULL
<	NULL
6,000	NULL
Null	NULL
18.7	NULL
1/5	NULL
>	NULL
6,000	NULL
Null	NULL
>	NULL
31.0	NULL
4/7	NULL
blasts	NULL
with	NULL
less	NULL
than	NULL
6,000	NULL
sites/cell	NULL
have	NULL
identical	NULL
median	NULL
survivals	NULL
of	NULL
19	NULL
months	NULL
.	NULL

One	NULL
patient	NULL
in	NULL
each	NULL
of	NULL
these	NULL
groups	NULL
remains	NULL
alive	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
in	NULL
patients	NULL
with	NULL
blasts	NULL
with	NULL
greater	NULL
than	NULL
6,000	NULL
sites/cell	NULL
(	NULL
all	NULL
null	NULL
)	NULL
,	NULL
the	NULL
median	NULL
survival	NULL
is	NULL
not	NULL
yet	NULL
reached	NULL
,	NULL
but	NULL
is	NULL
currently	NULL
greater	NULL
than	NULL
31	NULL
months	NULL
,	NULL
with	NULL
4	NULL
of	NULL
7	NULL
patients	NULL
still	NULL
alive	NULL
and	NULL
3	NULL
in	NULL
initial	NULL
remission	NULL
.	NULL

Conclusion	NULL
We	NULL
conclude	NULL
that	NULL
patients	NULL
with	NULL
high	NULL
receptor	NULL
levels	NULL
tend	NULL
to	NULL
have	NULL
null-cell	NULL
ALL	NULL
and	NULL
a	NULL
long	NULL
remission	NULL
duration	NULL
.	NULL

Patients	NULL
with	NULL
low	NULL
receptor	NULL
levels	NULL
have	NULL
T-lymphoblasts	NULL
and	NULL
a	NULL
short	NULL
remission	NULL
duration	NULL
.	NULL

Patients	NULL
with	NULL
intermediate	NULL
receptor	NULL
levels	NULL
had	NULL
an	NULL
intermediate	NULL
and	NULL
identical	NULL
remission	NULL
duration	NULL
,	NULL
regardless	NULL
of	NULL
cell	NULL
type	NULL
.	NULL

Thus	NULL
,	NULL
glucocorticoid	NULL
receptor	NULL
levels	NULL
appear	NULL
to	NULL
have	NULL
clinical	NULL
significance	NULL
independent	NULL
of	NULL
age	NULL
,	NULL
WBC	NULL
,	NULL
or	NULL
cell	NULL
type	NULL
.	NULL

Whether	NULL
their	NULL
entire	NULL
prognostic	NULL
significance	NULL
is	NULL
being	NULL
mediated	NULL
by	NULL
their	NULL
relationship	NULL
to	NULL
glucocorticofd	NULL
Tesponsiveness	NULL
is	NULL
not	NULL
known	NULL
.	NULL

It	NULL
is	NULL
certainly	NULL
possible	NULL
that	NULL
the	NULL
presence	NULL
of	NULL
these	NULL
binding	NULL
proteins	NULL
may	NULL
simply	NULL
be	NULL
an	NULL
important	NULL
biological	NULL
marker	NULL
associated	NULL
with	NULL
other	NULL
factors	NULL
which	NULL
are	NULL
related	NULL
to	NULL
chemotherapy	NULL
response	NULL
such	NULL
as	NULL
rate	NULL
of	NULL
growth	NULL
of	NULL
biochemical	NULL
differentiation	NULL
.	NULL

Some	NULL
support	NULL
for	NULL
this	NULL
latter	NULL
contention	NULL
is	NULL
derived	NULL
from	NULL
recent	NULL
studies	NULL
in	NULL
breast	NULL
cancer	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
breast	NULL
tumors	NULL
with	NULL
higher	NULL
mitotic	NULL
and	NULL
thymidine	NULL
labeling	NULL
indices	NULL
tend	NULL
to	NULL
be	NULL
estrogen	NULL
receptor	NULL
negative	NULL
(	NULL
24	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
we	NULL
have	NULL
recently	NULL
shown	NULL
that	NULL
there	NULL
is	NULL
a	NULL
strong	NULL
association	NULL
between	NULL
lack	NULL
of	NULL
estrogen	NULL
receptor	NULL
and	NULL
response	NULL
to	NULL
chemotherapy	NULL
(	NULL
17	NULL
)	NULL
.	NULL

The	NULL
point	NULL
to	NULL
be	NULL
made	NULL
is	NULL
that	NULL
specific	NULL
steroid	NULL
hormone	NULL
receptors	NULL
may	NULL
be	NULL
of	NULL
value	NULL
in	NULL
allowing	NULL
biochemical	NULL
subcategorization	NULL
of	NULL
some	NULL
human	NULL
cancers	NULL
and	NULL
that	NULL
these	NULL
subsets	NULL
may	NULL
be	NULL
associated	NULL
with	NULL
important	NULL
biological	NULL
and	NULL
clinical	NULL
differences	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Baxter	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
and	NULL
Forsham	NULL
,	NULL
P.	NULL
H.	NULL
Tissue	NULL
Effects	NULL
of	NULL
Glucocorticoids	NULL
.	NULL

Am	NULL
.	NULL

J	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
53	NULL
:	NULL
573-589	NULL
,	NULL
1972	NULL
.	NULL

2	NULL
.	NULL

Bourgeois	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Newby	NULL
,	NULL
R.	NULL
F.	NULL
Diploid	NULL
and	NULL
Haploid	NULL
States	NULL
of	NULL
the	NULL
Glucocorticoid	NULL
Receptor	NULL
Gene	NULL
of	NULL
Mouse	NULL
Lymphoid	NULL
Cell	NULL
Lines	NULL
.	NULL

Cell	NULL
,	NULL
11	NULL
:	NULL
423-430	NULL
,	NULL
1977	NULL
.	NULL

3	NULL
.	NULL

Bourgeois	NULL
,	NULL
S.	NULL
,	NULL
Newby	NULL
,	NULL
R.	NULL
F.	NULL
,	NULL
and	NULL
Huet	NULL
,	NULL
M.	NULL
Glucocorticoid	NULL
Resistance	NULL
in	NULL
Murine	NULL
Lymphoma	NULL
and	NULL
Thymoma	NULL
Lines	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
38	NULL
:	NULL
4279-4284	NULL
,	NULL
1978	NULL
.	NULL

4	NULL
.	NULL

Boyum	NULL
,	NULL
A	NULL
.	NULL

Isolation	NULL
of	NULL
Mononuclear	NULL
Cells	NULL
and	NULL
Granulocytes	NULL
from	NULL
Human	NULL
Blood	NULL
.	NULL

Scand	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Lab	NULL
.	NULL

Invest	NULL
.	NULL

,	NULL
21	NULL
(	NULL
Suppl	NULL
.	NULL

97	NULL
)	NULL
;	NULL
77-89	NULL
,	NULL
1968	NULL
.	NULL

5	NULL
.	NULL

Cidlowski	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Michaels	NULL
,	NULL
G.	NULL
A.	NULL
Alteration	NULL
in	NULL
Glucocorticoid	NULL
Binding	NULL
Site	NULL
Number	NULL
during	NULL
the	NULL
Cell	NULL
Cycle	NULL
in	NULL
HeLa	NULL
Cells	NULL
.	NULL

Nature	NULL
,	NULL
266	NULL
:	NULL
643-645	NULL
,	NULL
1977	NULL
.	NULL

6	NULL
.	NULL

Claman	NULL
,	NULL
H.	NULL
N.	NULL
Corticosteroids	NULL
and	NULL
Lymphoid	NULL
Cells	NULL
.	NULL

New	NULL
Engl	NULL
.	NULL

J	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
287	NULL
:	NULL
388-397	NULL
,	NULL
1972	NULL
.	NULL

7	NULL
.	NULL

Cline	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

Prediction	NULL
of	NULL
in	NULL
Vivo	NULL
Cytotoxicity	NULL
of	NULL
Chemotherapeutic	NULL
Agents	NULL
by	NULL
Their	NULL
Effect	NULL
on	NULL
Malignant	NULL
Leukocytes	NULL
in	NULL
Vitro	NULL
.	NULL

Blood	NULL
,	NULL
30	NULL
:	NULL
176-188	NULL
,	NULL
1967	NULL
.	NULL

8	NULL
.	NULL

Cline	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
Rosenbaum	NULL
,	NULL
E.	NULL
Prediction	NULL
of	NULL
in	NULL
Vivo	NULL
Cytotoxicity	NULL
of	NULL
Chemotherapeutic	NULL
Agents	NULL
by	NULL
Their	NULL
in	NULL
Vitro	NULL
Effect	NULL
on	NULL
Leukocytes	NULL
from	NULL
Patients	NULL
with	NULL
Acute	NULL
Leukemia	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
28	NULL
:	NULL
2516-2521	NULL
,	NULL
1968	NULL
.	NULL

4255	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1978	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

M.	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

E.	NULL
Lippman	NULL
et	NULL
al	NULL
.	NULL

.	NULL

Fauci	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
Dale	NULL
,	NULL
D.	NULL
C.	NULL
,	NULL
and	NULL
Balow	NULL
,	NULL
J.	NULL
E.	NULL
Glucocorticosteroid	NULL
Therapy	NULL
:	NULL
Mechanisms	NULL
of	NULL
Action	NULL
and	NULL
Clinical	NULL
Consideration	NULL
.	NULL

Ann	NULL
.	NULL

Internal	NULL
Med	NULL
.	NULL

,	NULL
84	NULL
:	NULL
304-315	NULL
,	NULL
1976	NULL
.	NULL

Goldin	NULL
,	NULL
A.	NULL
,	NULL
Sandberg	NULL
,	NULL
J.	NULL
,	NULL
Henderson	NULL
,	NULL
E.	NULL
,	NULL
Newman	NULL
,	NULL
J.	NULL
,	NULL
Frei	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Holland	NULL
,	NULL
J	NULL
.	NULL

The	NULL
Chemotherapy	NULL
of	NULL
Human	NULL
and	NULL
Animal	NULL
Acute	NULL
Leukemia	NULL
.	NULL

Cancer	NULL
Chemotherapy	NULL
Rept	NULL
.	NULL

,	NULL
55	NULL
:	NULL
309-507	NULL
,	NULL
1971	NULL
.	NULL

Homo	NULL
,	NULL
F.	NULL
,	NULL
Duval	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Meyer	NULL
,	NULL
P.	NULL
Etude	NULL
de	NULL
la	NULL
Liaison	NULL
de	NULL
la	NULL
Dexameth-asone	NULL
TritiÃ©	NULL
dans	NULL
les	NULL
Lymphocytes	NULL
de	NULL
Sujets	NULL
Normaux	NULL
et	NULL
LeuchÃ©emiques	NULL
.	NULL

Compt	NULL
.	NULL

Rend	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

Ser	NULL
.	NULL

D.	NULL
,	NULL
280	NULL
:	NULL
1923-1926	NULL
,	NULL
1975	NULL
.	NULL

Kersey	NULL
,	NULL
J.	NULL
,	NULL
Nesbit	NULL
,	NULL
M.	NULL
,	NULL
Haligren	NULL
,	NULL
H.	NULL
,	NULL
Sabad	NULL
,	NULL
A.	NULL
,	NULL
Yunis	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Gajl-Peczalsaka	NULL
,	NULL
K.	NULL
Evidence	NULL
for	NULL
the	NULL
Origin	NULL
of	NULL
Certain	NULL
Childhood	NULL
Acute	NULL
Lymphoblastic	NULL
Leukemias	NULL
and	NULL
Lymphosarcomas	NULL
in	NULL
Thymus-derived	NULL
Lymphocytes	NULL
.	NULL

Cancer	NULL
,	NULL
36	NULL
:	NULL
1348-1352	NULL
,	NULL
1975.	NULL
.	NULL

Kjelistrand	NULL
,	NULL
C.	NULL
M.	NULL
Side	NULL
Effects	NULL
of	NULL
Steroids	NULL
and	NULL
Their	NULL
Treatment	NULL
.	NULL

Trans-	NULL
plant	NULL
.	NULL

Proc	NULL
.	NULL

,	NULL
7	NULL
:	NULL
123-129	NULL
,	NULL
1975	NULL
.	NULL

Konior	NULL
,	NULL
G.	NULL
S.	NULL
,	NULL
Lippman	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Johnson	NULL
,	NULL
G.	NULL
E.	NULL
,	NULL
and	NULL
Leventhal	NULL
,	NULL
B.	NULL
G.	NULL
Correlation	NULL
of	NULL
Glucocorticoid	NULL
Receptor	NULL
(	NULL
GR	NULL
)	NULL
Levels	NULL
and	NULL
Complete	NULL
Remission	NULL
Duration	NULL
(	NULL
CRD	NULL
)	NULL
in	NULL
``	NULL
Poor	NULL
Prognosis	NULL
``	NULL
Acute	NULL
Lymphocytic	NULL
Leukemia	NULL
(	NULL
ALL	NULL
}	NULL
.	NULL

Proc	NULL
.	NULL

Am	NULL
.	NULL

Assoc	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
18	NULL
:	NULL
3653	NULL
,	NULL
1977	NULL
.	NULL

Konior	NULL
,	NULL
G.	NULL
S.	NULL
,	NULL
Lippman	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Johnson	NULL
,	NULL
G.	NULL
E.	NULL
,	NULL
and	NULL
Leventhal	NULL
,	NULL
B.	NULL
G.	NULL
Glucocorticoid	NULL
Receptors	NULL
in	NULL
Subpopulations	NULL
of	NULL
Childhood	NULL
Acute	NULL
Lymphocytic	NULL
Leukemia	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
37	NULL
:	NULL
2688-2695	NULL
,	NULL
1977	NULL
.	NULL

Lippman	NULL
,	NULL
M.	NULL
E.	NULL
Glucocorticoid	NULL
Receptor	NULL
.	NULL

in	NULL
:	NULL
G.	NULL
S.	NULL
Levey	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Hormone-Receptor	NULL
Interaction	NULL
,	NULL
pp	NULL
.	NULL

221-242	NULL
.	NULL

New	NULL
York	NULL
:	NULL
Marce	NULL
!	NULL

Dekker	NULL
,	NULL
1976	NULL
.	NULL

Lippman	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Allegra	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Thompson	NULL
,	NULL
E.	NULL
B.	NULL
,	NULL
Simon	NULL
,	NULL
R.	NULL
,	NULL
Barlock	NULL
,	NULL
A.	NULL
,	NULL
Green	NULL
,	NULL
L.	NULL
,	NULL
Huff	NULL
,	NULL
K.	NULL
K.	NULL
,	NULL
Do	NULL
,	NULL
H.	NULL
T.	NULL
,	NULL
Aitken	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
and	NULL
Warren	NULL
,	NULL
R.	NULL
Lack	NULL
of	NULL
Estrogen	NULL
Receptor	NULL
is	NULL
Associated	NULL
with	NULL
an	NULL
Increased	NULL
Response	NULL
Rate	NULL
to	NULL
Cytotoxic	NULL
Chemotherapy	NULL
in	NULL
Metastatic	NULL
Breast	NULL
Cancer	NULL
.	NULL

New	NULL
Engl	NULL
.	NULL

J	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
298	NULL
:	NULL
1223-1228	NULL
,	NULL
1978	NULL
.	NULL

Lippman	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
and	NULL
Barr	NULL
,	NULL
R.	NULL
Glucocorticoid	NULL
Receptors	NULL
in	NULL
Purified	NULL
Subpopulations	NULL
of	NULL
Human	NULL
Peripheral	NULL
Blood	NULL
Lymphocytes	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
118	NULL
:	NULL
1977-2003	NULL
,	NULL
1977.	NULL
.	NULL

Lippman	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Halterman	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
Leventhal	NULL
,	NULL
B.	NULL
G.	NULL
,	NULL
Perry	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
E.	NULL
B.	NULL
Glucocorticoid-binding	NULL
Proteins	NULL
in	NULL
Acute	NULL
Lymphoblastic	NULL
Leukemic	NULL
Blast	NULL
Cells	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

,	NULL
52	NULL
:	NULL
1715-1725	NULL
,	NULL
1973	NULL
.	NULL

Lippman	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Halterman	NULL
,	NULL
R.	NULL
,	NULL
Perry	NULL
,	NULL
S.	NULL
,	NULL
Leventhal	NULL
,	NULL
8.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
E.	NULL
B.	NULL
Glucocorticoid	NULL
Binding	NULL
Proteins	NULL
in	NULL
Human	NULL
Leukemia	NULL
Lymphoblasts	NULL
.	NULL

Nature	NULL
New	NULL
Biol	NULL
.	NULL

,	NULL
242	NULL
:	NULL
157-158	NULL
,	NULL
1973	NULL
.	NULL

Lippman	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Perry	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
E.	NULL
B.	NULL
Cytoplasmic	NULL
Glucocorticoid-binding	NULL
Proteins	NULL
in	NULL
Glucocorticoid-unresponsive	NULL
Human	NULL
and	NULL
Mouse	NULL
Leukemic	NULL
Cell	NULL
Lines	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
34	NULL
:	NULL
1572-1576	NULL
,	NULL
1974	NULL
.	NULL

Livingston	NULL
,	NULL
R.	NULL
B.	NULL
,	NULL
and	NULL
Carter	NULL
,	NULL
S.	NULL
K	NULL
.	NULL

(	NULL
eds	NULL
.	NULL
)	NULL

.	NULL

Single	NULL
Agents	NULL
in	NULL
Cancer	NULL
Chemotherapy	NULL
.	NULL

New	NULL
York	NULL
:	NULL
Plenum	NULL
Press	NULL
,	NULL
1970	NULL
.	NULL

McGuire	NULL
,	NULL
W.	NULL
L.	NULL
,	NULL
Carbone	NULL
,	NULL
P.	NULL
P.	NULL
,	NULL
and	NULL
Vollmer	NULL
,	NULL
E.	NULL
P	NULL
.	NULL

(	NULL
eds	NULL
.	NULL
)	NULL

.	NULL

Estrogen	NULL
Receptors	NULL
in	NULL
Human	NULL
Breast	NULL
Cancer	NULL
.	NULL

New	NULL
York	NULL
:	NULL
Raven	NULL
Press	NULL
,	NULL
1975	NULL
.	NULL

Meyer	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Rao	NULL
,	NULL
B.	NULL
R.	NULL
,	NULL
Stevens	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
and	NULL
White	NULL
,	NULL
W.	NULL
L.	NULL
Low	NULL
Incidence	NULL
4256	NULL
25	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39.	NULL
of	NULL
Estrogen	NULL
Receptor	NULL
in	NULL
Breast	NULL
Carcinomas	NULL
with	NULL
Rapid	NULL
Rates	NULL
of	NULL
Cellular	NULL
Replication	NULL
.	NULL

Cancer	NULL
,	NULL
39	NULL
:	NULL
2934-2947	NULL
,	NULL
1977	NULL
.	NULL

Moon	NULL
,	NULL
H.	NULL
Inhibition	NULL
of	NULL
Somatic	NULL
Growth	NULL
in	NULL
Castrate	NULL
Rats	NULL
with	NULL
Pituitary	NULL
Extract	NULL
.	NULL

Proc	NULL
.	NULL

Soc	NULL
.	NULL

Expti	NULL
.	NULL

Biol	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
37	NULL
:	NULL
34-36	NULL
,	NULL
1937.	NULL
.	NULL

Munck	NULL
,	NULL
A.	NULL
,	NULL
Wira	NULL
,	NULL
C.	NULL
,	NULL
Young	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Mosher	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Hallahan	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Bell	NULL
,	NULL
P.	NULL
A.	NULL
Glucocorticoid-Receptor	NULL
Complexes	NULL
and	NULL
the	NULL
Earliest	NULL
Steps	NULL
in	NULL
the	NULL
Action	NULL
of	NULL
Glucocorticoids	NULL
on	NULL
Thymus	NULL
Cells	NULL
.	NULL

J.	NULL
Steroid	NULL
Biochem	NULL
.	NULL

,	NULL
3	NULL
:	NULL
567-578	NULL
,	NULL
1972	NULL
.	NULL

Neifeld	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Lippman	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
and	NULL
Tormey	NULL
,	NULL
D.	NULL
C.	NULL
Steroid	NULL
Hormone	NULL
Receptors	NULL
in	NULL
Normal	NULL
Human	NULL
Lymphocytes	NULL
.	NULL

Induction	NULL
of	NULL
Glucocorticoid	NULL
Receptor	NULL
Activity	NULL
by	NULL
Phytohemagglutinin	NULL
Stimulation	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
254	NULL
:	NULL
2972-2977	NULL
,	NULL
1977	NULL
.	NULL

Pratt	NULL
,	NULL
W.	NULL
B.	NULL
,	NULL
and	NULL
Aronow	NULL
,	NULL
L.	NULL
The	NULL
Effect	NULL
of	NULL
Glucocorticoids	NULL
on	NULL
Protein	NULL
and	NULL
Nucleic	NULL
Acid	NULL
Synthesis	NULL
in	NULL
Mouse	NULL
Fibroblasts	NULL
Growing	NULL
in	NULL
Vitro	NULL
.	NULL

J.	NULL
Biot	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
241	NULL
:	NULL
5244-5250	NULL
,	NULL
1966	NULL
.	NULL

Selye	NULL
,	NULL
H.	NULL
Studies	NULL
on	NULL
Adaptation	NULL
.	NULL

Endocrinology	NULL
,	NULL
21	NULL
:	NULL
169-188	NULL
,	NULL
1937	NULL
.	NULL

Sen	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Borelia	NULL
,	NULL
L.	NULL
Clinical	NULL
Importance	NULL
of	NULL
Lymphoblasts	NULL
with	NULL
T	NULL
Markers	NULL
in	NULL
Childhood	NULL
Acute	NULL
Leukemia	NULL
.	NULL

New	NULL
Engl	NULL
.	NULL

J	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
292	NULL
:	NULL
828-832	NULL
,	NULL
1975	NULL
.	NULL

Sibley	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
and	NULL
Tomkins	NULL
,	NULL
G.	NULL
M.	NULL
Isolation	NULL
of	NULL
Lymphoma	NULL
Cell	NULL
Variants	NULL
Resistant	NULL
to	NULL
Killing	NULL
by	NULL
Glucocorticoids	NULL
.	NULL

Cell	NULL
,	NULL
2	NULL
:	NULL
213-220	NULL
,	NULL
1974	NULL
.	NULL

Sibley	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
and	NULL
Tomkins	NULL
,	NULL
G.	NULL
M.	NULL
Mechanisms	NULL
of	NULL
Steroid	NULL
Resistance	NULL
.	NULL

Cell	NULL
,	NULL
2	NULL
:	NULL
221-227	NULL
,	NULL
1974	NULL
.	NULL

Smith	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
Kennedy	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
and	NULL
Munck	NULL
,	NULL
A.	NULL
U.	NULL
Glucocorticoid	NULL
Receptors	NULL
and	NULL
Glucocorticoid	NULL
Sensitivity	NULL
of	NULL
Mitogen	NULL
Stimulated	NULL
and	NULL
Unstimulated	NULL
Human	NULL
Lymphocytes	NULL
.	NULL

Nature	NULL
,	NULL
265	NULL
:	NULL
523-526	NULL
,	NULL
1977	NULL
.	NULL

Stevens	NULL
,	NULL
W.	NULL
,	NULL
Colissides	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Dougherty	NULL
,	NULL
T.	NULL
F.	NULL
A	NULL
Time	NULL
Study	NULL
on	NULL
the	NULL
Effect	NULL
of	NULL
Cortisol	NULL
on	NULL
the	NULL
Incorporation	NULL
of	NULL
Thymidine-2-C'*	NULL
into	NULL
Nucleic	NULL
Acids	NULL
of	NULL
Mouse	NULL
Lymphatic	NULL
Tissues	NULL
.	NULL

Endocrinology	NULL
,	NULL
78	NULL
:	NULL
600-604	NULL
,	NULL
1966.	NULL
.	NULL

Thompson	NULL
,	NULL
E.	NULL
B.	NULL
,	NULL
and	NULL
Lippman	NULL
,	NULL
M.	NULL
E.	NULL
Mechanism	NULL
of	NULL
Action	NULL
of	NULL
Gluco-	NULL
corticoids	NULL
.	NULL

Metabolism	NULL
,	NULL
23	NULL
:	NULL
159-202	NULL
,	NULL
1974.	NULL
.	NULL

Tormey	NULL
,	NULL
D.	NULL
C.	NULL
,	NULL
Fudenberg	NULL
,	NULL
H.	NULL
H.	NULL
,	NULL
and	NULL
Kamin	NULL
,	NULL
R.	NULL
M.	NULL
Effect	NULL
of	NULL
Predniso-	NULL
lone	NULL
on	NULL
Synthesis	NULL
of	NULL
DNA	NULL
and	NULL
RNA	NULL
by	NULL
Human	NULL
Lymphocytes	NULL
in	NULL
Vitro	NULL
.	NULL

Nature	NULL
,	NULL
213	NULL
:	NULL
281-282	NULL
,	NULL
1967	NULL
.	NULL

Tsukimoto	NULL
,	NULL
I.	NULL
,	NULL
Wong	NULL
,	NULL
K.	NULL
Y.	NULL
,	NULL
and	NULL
Lampkin	NULL
,	NULL
B.	NULL
C.	NULL
Surface	NULL
Markers	NULL
and	NULL
Prognostic	NULL
Factors	NULL
in	NULL
Acute	NULL
Lymphoblastic	NULL
Leukemia	NULL
.	NULL

New	NULL
Engl	NULL
.	NULL

J	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
294	NULL
:	NULL
245-248	NULL
,	NULL
1976	NULL
.	NULL

Vietti	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
Sullivan	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Berry	NULL
,	NULL
D.	NULL
H.	NULL
,	NULL
Hardy	NULL
,	NULL
T.	NULL
,	NULL
Haggard	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Blattner	NULL
,	NULL
R.	NULL
The	NULL
Response	NULL
of	NULL
Acute	NULL
Childhood	NULL
Leukemia	NULL
to	NULL
an	NULL
Initial	NULL
and	NULL
a	NULL
Second	NULL
Course	NULL
of	NULL
Prednisolone	NULL
.	NULL

J	NULL
.	NULL

Pediat	NULL
.	NULL

,	NULL
66	NULL
:	NULL
18-26	NULL
,	NULL
1965	NULL
.	NULL

Yamamoto	NULL
,	NULL
K.	NULL
R.	NULL
,	NULL
Stampfer	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
and	NULL
Tomkins	NULL
,	NULL
G.	NULL
M.	NULL
Receptors	NULL
from	NULL
Glucocorticoid-sensitive	NULL
Lymphoma	NULL
Cells	NULL
and	NULL
Two	NULL
Classes	NULL
of	NULL
Insensitive	NULL
Clones	NULL
:	NULL
Physical	NULL
and	NULL
DNA-binding	NULL
Properties	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
,	NULL
71	NULL
:	NULL
3901-3905	NULL
,	NULL
1974	NULL
.	NULL

CANCER	NULL
RESEARCH	NULL
VOL	NULL
.	NULL

38	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1978	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

AAGR	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
Cancer	NULL
Research	NULL
The	NULL
Journal	NULL
of	NULL
Cancer	NULL
Research	NULL
(	NULL
1916-1930	NULL
)	NULL
|	NULL
The	NULL
American	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1931-1940	NULL
)	NULL
Clinical	NULL
Implications	NULL
of	NULL
Glucocorticoid	NULL
Receptors	NULL
in	NULL
Human	NULL
Leukemia	NULL
Marc	NULL
E.	NULL
Lippman	NULL
,	NULL
Geraldine	NULL
Konior	NULL
Yarbro	NULL
and	NULL
Brigid	NULL
G.	NULL
Leventhal	NULL
Cancer	NULL
Res	NULL
1978	NULL
;	NULL
38:4251-4256	NULL
.	NULL

Updated	NULL
version	NULL
_	NULL
Access	NULL
the	NULL
most	NULL
recent	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/38/11	NULL
Part	NULL
2/4251	NULL
E-mail	NULL
alerts	NULL
_	NULL
Sign	NULL
up	NULL
to	NULL
receive	NULL
free	NULL
email-alerts	NULL
related	NULL
to	NULL
this	NULL
article	NULL
or	NULL
journal	NULL
.	NULL

Reprints	NULL
and	NULL
_	NULL
To	NULL
order	NULL
reprints	NULL
of	NULL
this	NULL
article	NULL
or	NULL
to	NULL
subscribe	NULL
to	NULL
the	NULL
journal	NULL
,	NULL
contact	NULL
the	NULL
AACR	NULL
Publications	NULL
Subscriptions	NULL
_	NULL
Department	NULL
at	NULL
pubs	NULL
@	NULL
aacr.org	NULL
.	NULL

Permissions	NULL
_	NULL
To	NULL
request	NULL
permission	NULL
to	NULL
re-use	NULL
all	NULL
or	NULL
part	NULL
of	NULL
this	NULL
article	NULL
,	NULL
use	NULL
this	NULL
link	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/38/11	NULL
Part	NULL
2/4251	NULL
.	NULL

Click	NULL
on	NULL
``	NULL
Request	NULL
Permissions	NULL
``	NULL
which	NULL
will	NULL
take	NULL
you	NULL
to	NULL
the	NULL
Copyright	NULL
Clearance	NULL
Center	NULL
's	NULL
(	NULL
CCC	NULL
)	NULL
Rightslink	NULL
site	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1978	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

